Amedeo Smart

Free Medical Literature Service

 

Amedeo

Leukemia
  Free Subscription

Articles published in
Blood
    April 2024
  1. LAMBLE AJ, Rau RE
    IFN-gamma and CD38 in AML: a T-cell engagement made in heaven?
    Blood. 2024;143:1556-1557.
    >> Share

  2. CUNEO A, Ghia P
    Ibrutinib in CLL: benefit for all?
    Blood. 2024;143:1558-1559.
    >> Share

  3. BUFFET R
    How lipid coating soothes the gut in AML therapy.
    Blood. 2024;143:1559-1561.
    >> Share

  4. RENGA G, Nunzi E, Stincardini C, Pariano M, et al
    CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis.
    Blood. 2024;143:1628-1645.
    >> Share

  5. WOYACH JA, Perez Burbano G, Ruppert AS, Miller C, et al
    Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
    Blood. 2024;143:1616-1627.
    >> Share

  6. LANGERBEINS P, Giza A, Robrecht S, Cramer P, et al
    Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
    Blood. 2024 Apr 15:blood.2023022564. doi: 10.1182/blood.2023022564.
    >> Share

  7. BULLINGER L, Kronke J
    Making AML fly too close to the sun.
    Blood. 2024;143:1438-1439.
    >> Share

  8. BOURGEOIS W, Cutler JA, Aubrey BJ, Wenge DV, et al
    Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
    Blood. 2024;143:1513-1527.
    >> Share

  9. MARCAIS A
    Targeting PD-L1 to treat ATLL?
    Blood. 2024;143:1320-1322.
    >> Share

  10. MINA A, Greenberg PL, Deeg HJ
    How I reduce and treat posttransplant relapse of MDS.
    Blood. 2024;143:1344-1354.
    >> Share

  11. BASTIAN L, Beder T, Barz MJ, Bendig S, et al
    Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.
    Blood. 2024;143:1391-1398.
    >> Share

    March 2024
  12. INESS AN, Bachireddy P
    GPR56 in GVL: marker or mechanism?
    Blood. 2024;143:1206-1207.
    >> Share

  13. MATHIOUDAKI A, Wang X, Sedloev D, Huth R, et al
    The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature.
    Blood. 2024;143:1269-1281.
    >> Share

  14. BAUMGARTNER F, Baer C, Bamopoulos S, Ayoub E, et al
    Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022.
    Blood. 2024;143:1139-1156.
    >> Share

  15. KLEIN K, Kollmann S, Hiesinger A, List J, et al
    A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia.
    Blood. 2024 Mar 18:blood.2023022655. doi: 10.1182/blood.2023022655.
    >> Share

  16. AZOULAY E, Maertens J, Lemiale V
    How I manage acute respiratory failure in patients with hematological malignancies.
    Blood. 2024;143:971-982.
    >> Share

  17. MACK EA, Dougher MC, Ginda AM, Cahill C, et al
    Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis.
    Blood. 2024;143:1049-1054.
    >> Share

  18. FELIPE FUMERO E, Walter C, Frenz JM, Seifert FC, et al
    Epigenetic control over cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia.
    Blood. 2024 Mar 8:blood.2023021640. doi: 10.1182/blood.2023021640.
    >> Share

  19. CHALANDON Y, Rousselot P, Chevret S, Cayuela JM, et al
    Nilotinib with or without cytarabine for Philadelphia positive acute lymphoblastic leukemia.
    Blood. 2024 Mar 7:blood.2023023502. doi: 10.1182/blood.2023023502.
    >> Share


  20. Colom Diaz PA, Mistry JJ, Trowbridge JJ. Hematopoietic stem cell aging and leukemia transformation. Blood. 2023;142(6):533-542.
    Blood. 2024;143:939.
    >> Share

  21. AHMED R, Feldman AL
    Occult ALK-negative anaplastic large cell lymphoma complicating chronic lymphocytic leukemia.
    Blood. 2024;143:938.
    >> Share

  22. O'CONNOR D, Valle-Inclan JE, Conde L, Bloye G, et al
    Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL.
    Blood. 2024;143:933-937.
    >> Share

  23. ESCHERICH CS, Chen W, Li Y, Yang W, et al
    Germline Genetic NBN Variation and Predisposition to B-cell Acute Lymphoblastic Leukemia in Children.
    Blood. 2024 Mar 6:blood.2023023336. doi: 10.1182/blood.2023023336.
    >> Share

  24. AVILA AVILA A, Nuantang K, Oliveira ML, Druillennec S, et al
    Targeting the TNF/IAP pathway synergizes with anti-CD3 immunotherapy in T-Cell Acute Lymphoblastic Leukemia.
    Blood. 2024 Mar 4:blood.2023022455. doi: 10.1182/blood.2023022455.
    >> Share

    February 2024
  25. BARROS PINTO MP, Cabecadas J
    Binucleated and cloverleaf-shaped nucleus in lymphocytes in CLL.
    Blood. 2024;143:833.
    >> Share

  26. MURTADHA M, Park M, Zhu Y, Caserta E, et al
    CD38-directed, single-chain T cell-engager targets leukemia stem cells through IFNgamma-induced CD38 expression.
    Blood. 2024 Feb 26:blood.2023021570. doi: 10.1182/blood.2023021570.
    >> Share

  27. VAN OUTERSTERP I, Tasian SK, Reichert CE, Boeree A, et al
    Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: The role of kinase type and SH3 domain.
    Blood. 2024 Feb 23:blood.2023023120. doi: 10.1182/blood.2023023120.
    >> Share

  28. BARBOSA K, Deshpande A, Perales M, Xiang P, et al
    Transcriptional control of leukemogenesis by the chromatin reader SGF29.
    Blood. 2024;143:697-712.
    >> Share

  29. BISWAS J, Abdel-Wahab O
    A new SAGA for AML: targeting SGF29 in AML.
    Blood. 2024;143:657-658.
    >> Share

  30. SUMMERS RJ, Teachey DT, Hunger SP
    How I treat early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) in children.
    Blood. 2024 Feb 16:blood.2023023155. doi: 10.1182/blood.2023023155.
    >> Share

  31. MENSURADO S, Condeco AC, Sanchez-Martinez D, Shirley S, et al
    CD155/PVR determines Acute Myeloid Leukemia targeting by Delta One T cells.
    Blood. 2024 Feb 16:blood.2023022992. doi: 10.1182/blood.2023022992.
    >> Share

  32. COTY-FATTAL Z, Richardson AI
    A 3-year-old with chronic myeloid leukemia.
    Blood. 2024;143:651.
    >> Share

  33. BARAJAS JM, Rasouli M, Umeda M, Hiltenbrand R, et al
    Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors.
    Blood. 2024;143:619-630.
    >> Share

  34. BERNT KM
    Menin dependence: UBTF-ITD AML joins the club.
    Blood. 2024;143:567-569.
    >> Share

  35. CHEN B, Abdel-Wahab O
    Targeting the cBAF complex in T-ALL.
    Blood. 2024;143:566-567.
    >> Share

  36. ARBER C
    Two to tango: engineered T cells against AML.
    Blood. 2024;143:476-478.
    >> Share

  37. QIU L, Naresh KN
    Mature plasmacytoid dendritic cell proliferation in association with mixed-phenotype acute leukemia, T/myeloid.
    Blood. 2024;143:561.
    >> Share

  38. DAO T, Xiong G, Mun SS, Meyerberg J, et al
    A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML.
    Blood. 2024;143:507-521.
    >> Share

  39. BHATT VR, Uy GL, Klepin HD
    Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action.
    Blood. 2024;143:483-487.
    >> Share

  40. ROUSSELOT P
    Old rivals become new friends.
    Blood. 2024;143:380-382.
    >> Share

  41. ORDONEZ MAZARIEGOS EE, Dimopoulos YP
    A rare case of ICUS progressing to MDS with isolated isochromosome 17q and AML.
    Blood. 2024;143:473.
    >> Share

    January 2024
  42. GU H, Chen C, Hou ZS, He XD, et al
    PI3Kgamma maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway.
    Blood. 2024 Jan 25:blood.2023022202. doi: 10.1182/blood.2023022202.
    >> Share

  43. SCHRAW JM
    Anticancer drug exposure in utero and leukemia.
    Blood. 2024;143:293-294.
    >> Share

  44. BARATA JT
    Darwin, MSI2, and relapse in T-ALL.
    Blood. 2024;143:294-296.
    >> Share

  45. SAHASRABUDHE KD, Mims AS
    MRD in AML: who, what, when, where, and how?
    Blood. 2024;143:296-298.
    >> Share

  46. OTHMAN J, Tiong IS, O'Nions J, Dennis M, et al
    Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.
    Blood. 2024;143:336-341.
    >> Share

  47. LEUNG WK, Torres Chavez AG, French-Kim M, Shafer P, et al
    Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia.
    Blood. 2024 Jan 19:blood.2023021979. doi: 10.1182/blood.2023021979.
    >> Share

  48. WEINACHT KG
    The rise of haplo: a quest for the perfect graft.
    Blood. 2024;143:193-195.
    >> Share


  49. alphabetaT/CD19-depleted haploHSCT for pediatric leukemia.
    Blood. 2024;143:291.
    >> Share

  50. CHEN H, Wang H
    Acute myeloid leukemia with GATA2 and WT1 mutations mimicking acute promyelocytic leukemia.
    Blood. 2024;143:290.
    >> Share

  51. SAULTIER P, Michel G
    How I Treat: long-term survivors of childhood acute leukemia.
    Blood. 2024 Jan 16:blood.2023019804. doi: 10.1182/blood.2023019804.
    >> Share

  52. BULDINI B, Varotto E, Maurer-Granofszky M, Gaipa G, et al
    CD371+ pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment.
    Blood. 2024 Jan 12:blood.2023021952. doi: 10.1182/blood.2023021952.
    >> Share


  53. Bamezai S, Pulikkottil AJ, Yadav T, et al. A noncanonical enzymatic function of PIWIL4 maintains genomic integrity and leukemic growth in AML. Blood. 2023;142(1):90-105.
    Blood. 2024;143:184.
    >> Share

  54. DIMOPOULOS YP, Loghavi S
    Acute leukemia of ambiguous lineage with BCL11B rearrangement.
    Blood. 2024;143:183.
    >> Share

  55. GHORASHIAN S, Lucchini G, Richardson R, Nguyen K, et al
    CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL.
    Blood. 2024;143:118-123.
    >> Share

  56. VELTMAAT L, Cortes J
    Arterio-Occlusive Events Among Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitors.
    Blood. 2024 Jan 9:blood.2023022403. doi: 10.1182/blood.2023022403.
    >> Share

  57. MOSS P
    Ibrutinib reversal of immune exhaustion in CLL.
    Blood. 2024;143:5-7.
    >> Share


  58. Kennedy E, Coulter E, Halliwell E, et al. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood. 2021;137(22):3064-3078.
    Blood. 2024;143:93.
    >> Share

  59. PAPAZOGLOU D, Wang XV, Shanafelt TD, Lesnick CE, et al
    Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial.
    Blood. 2024;143:57-63.
    >> Share

    December 2023
  60. QUESSADA J, Loosveld M
    CBFB::MYH11 fusion in a nonmonocytic acute myeloid leukemia.
    Blood. 2023;142:2332.
    >> Share

  61. HASSERJIAN RP, Germing U, Malcovati L
    Diagnosis and classification of myelodysplastic syndromes.
    Blood. 2023;142:2247-2257.
    >> Share

  62. DEZERN AE, Greenberg PL
    The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes.
    Blood. 2023;142:2258-2267.
    >> Share

  63. CHIBA M, Shimono J, Suto K, Ishio T, et al
    Whole genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in Adult T-cell leukemia/lymphoma.
    Blood. 2023 Dec 24:blood.2023021423. doi: 10.1182/blood.2023021423.
    >> Share

  64. BRECCIA M
    A traffic light for TFR by lineage-specific MRD.
    Blood. 2023;142:2129-2130.
    >> Share

  65. FU L, Gong S
    KMT2A-rearranged B-lymphoblastic leukemia/lymphoma with surface light chain restriction and lacking immature markers.
    Blood. 2023;142:2220.
    >> Share


  66. NIH natural history study of FPDMM patients.
    Blood. 2023;142:2222.
    >> Share

  67. FRANK D, Patnana PK, Vorwerk J, Mao L, et al
    Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.
    Blood. 2023;142:2175-2191.
    >> Share

  68. CUNNINGHAM L, Merguerian M, Calvo KR, Davis J, et al
    Natural history study of patients with familial platelet disorder with associated myeloid malignancy.
    Blood. 2023;142:2146-2158.
    >> Share

  69. MARCELLINO BK
    PPM1D inhibition may allow us to WIP leukemia.
    Blood. 2023;142:2040-2042.
    >> Share

  70. COUSTAN-SMITH E, Conter V
    Closing the circle for ETP ALL.
    Blood. 2023;142:2039-2040.
    >> Share

  71. WOOD BL, Devidas M, Summers RJ, Chen Z, et al
    Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study.
    Blood. 2023;142:2069-2078.
    >> Share

  72. DIMITRIOU M, Mortera-Blanco T, Tobiasson M, Mazzi S, et al
    Identification and surveillance of rare relapse-initiating stem cells during complete remission post-transplantation.
    Blood. 2023 Dec 14:blood.2023022851. doi: 10.1182/blood.2023022851.
    >> Share

  73. PALM-APERGI C
    PLK4, a potential target against AML.
    Blood. 2023;142:1941-1942.
    >> Share

  74. STONE RM
    FLT(3)-ing about: the search for the best inhibitor.
    Blood. 2023;142:1937-1938.
    >> Share

  75. MAN CH, Lam W, Dang CC, Zeng XY, et al
    Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML.
    Blood. 2023;142:2002-2015.
    >> Share

  76. FLEMING S, Tsai XC, Morris R, Hou HA, et al
    TP53 status and impact on AML prognosis within the ELN 2022 risk classification.
    Blood. 2023;142:2029-2033.
    >> Share

  77. LOO S, Roberts AW, Anstee NS, Kennedy GA, et al
    Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.
    Blood. 2023;142:1960-1971.
    >> Share

    November 2023
  78. BEWERSDORF JP, How J, Masarova L, Bose P, et al
    Moving toward disease modification in polycythemia vera.
    Blood. 2023;142:1859-1870.
    >> Share

  79. DAVIDS MS
    Functional cure reported in CLL.
    Blood. 2023;142:1761-1763.
    >> Share

  80. LIN E, Chen W
    Acute myeloid leukemia with NUP98::HOXA9 mimicking acute promyelocytic leukemia.
    Blood. 2023;142:1845.
    >> Share


  81. Wei AH, Panayiotidis P, Montesinos P, et al. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. Blood. 2022;140(25):2754-2756.
    Blood. 2023;142:1846-1847.
    >> Share

  82. THOMPSON PA, Bazinet A, Wierda WG, Tam CS, et al
    Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.
    Blood. 2023;142:1784-1788.
    >> Share

  83. KIM R, Bergugnat H, Pastoret C, Pasquier F, et al
    Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study.
    Blood. 2023;142:1806-1817.
    >> Share

  84. ROLLIG C
    Gemtuzumab ozogamicin in AML: the next chapter.
    Blood. 2023;142:1673-1674.
    >> Share

  85. STRASSER B, Haushofer A
    Cabot rings in chronic myelomonocytic leukemia.
    Blood. 2023;142:1757.
    >> Share

  86. FREEMAN SD, Thomas A, Thomas I, Hills RK, et al
    Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
    Blood. 2023;142:1697-1707.
    >> Share


  87. Fractionated vs single-dose gemtuzumab for AML.
    Blood. 2023;142:1759.
    >> Share

  88. BUENO C, Torres-Ruiz R, Velasco-Hernandez T, Molina O, et al
    A human genome editing-based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features.
    Blood. 2023;142:1752-1756.
    >> Share

  89. THOL FR, Dohner H, Ganser A
    How I treat refractory and relapsed acute myeloid leukemia.
    Blood. 2023 Nov 9:blood.2023022481. doi: 10.1182/blood.2023022481.
    >> Share

  90. VYAS P
    Changing treatment changing prognosis of mutations.
    Blood. 2023;142:1583-1585.
    >> Share

  91. AOKI K, Hyuga M, Tarumoto Y, Nishibuchi G, et al
    Canonical BAF complex regulates the oncogenic program in human T-cell acute lymphoblastic leukemia.
    Blood. 2023 Nov 3:blood.2023020857. doi: 10.1182/blood.2023020857.
    >> Share

    October 2023
  92. JABBOUR EJ, Haddad FG, Short NJ, Senapati J, et al
    Phase II Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission.
    Blood. 2023 Oct 25:blood.2023022330. doi: 10.1182/blood.2023022330.
    >> Share

  93. MALAGA ML, Carrillo LF
    FISH-negative, karyotype-negative acute promyelocytic leukemia.
    Blood. 2023;142:1328.
    >> Share

  94. PRINCE HM
    Blocked addiction to IL-15 for treating T-LGLL.
    Blood. 2023;142:1258-1260.
    >> Share

  95. XIE J, Bao X, Xue SL, Shen H, et al
    Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML.
    Blood. 2023;142:1323-1327.
    >> Share

  96. ZHANG J, Duan Y, Wu P, Chang Y, et al
    Clonal Evolution Dissection Reveals High MSI2 Level Promotes Chemo-resistance in T-cell Acute Lymphoblastic Leukemia.
    Blood. 2023 Oct 6:blood.2023020490. doi: 10.1182/blood.2023020490.
    >> Share

  97. KUMAR J, Petrova-Drus K
    Acute leukemia with predominantly myeloid differentiation and TBL1XR1::CSF1R fusion.
    Blood. 2023;142:1253.
    >> Share

  98. CHELOOR KOVILAKAM S, Gu M, Dunn WG, Marando L, et al
    Prevalence and significance of DDX41 gene variants in the general population.
    Blood. 2023;142:1185-1192.
    >> Share

  99. YAMAMOTO S, Sanefuji M, Suzuki M, Sonoda Y, et al
    Pediatric leukemia and maternal occupational exposure to anticancer drugs: The Japan Environment and Children's Study.
    Blood. 2023 Oct 3:blood.2023021008. doi: 10.1182/blood.2023021008.
    >> Share

    September 2023
  100. GOEDE V
    Frailty is also a target for targeted drugs in CLL.
    Blood. 2023;142:1107-1108.
    >> Share

  101. VAN DER STRATEN L, Stege CAM, Kersting S, Nasserinejad K, et al
    Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.
    Blood. 2023;142:1131-1142.
    >> Share

  102. MERLI P, Algeri M, Galaverna F, Bertaina V, et al
    TCRalphabeta/CD19 cell-depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis.
    Blood. 2023 Sep 22:blood.2023021336. doi: 10.1182/blood.2023021336.
    >> Share

  103. LI S, Adams PD
    Targeting the epichaperome to combat AML.
    Blood. 2023;142:1031-1032.
    >> Share


  104. Gribben JG. Targeting the methylome to improve CLL outcome. Blood. 2023;142(1):4-6.
    Blood. 2023;142:1103.
    >> Share

  105. CARTER BZ, Mak PY, Muftuoglu M, Tao W, et al
    Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
    Blood. 2023;142:1056-1070.
    >> Share

  106. UCKELMANN HJ, Klusmann JH
    Double trouble: IRAK1/4 inhibitors in AML/MDS.
    Blood. 2023;142:945-946.
    >> Share

  107. KWOK M, Stankovic T
    CLL patients: GIVe me three!
    Blood. 2023;142:941-943.
    >> Share

  108. HUBER H, Tausch E, Schneider C, Edenhofer S, et al
    Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
    Blood. 2023;142:961-972.
    >> Share

  109. BENNETT J, Ishikawa C, Agarwal P, Yeung J, et al
    Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML.
    Blood. 2023;142:989-1007.
    >> Share

  110. FEI MY, Wang Y, Chang BH, Xue K, et al
    The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment.
    Blood. 2023;142:903-917.
    >> Share

    August 2023
  111. ZHANG Q, Li H, Chen X, Gu F, et al
    Identifying STRN3-RARA as a new fusion gene for acute promyelocytic leukemia.
    Blood. 2023 Aug 25:blood.2023020619. doi: 10.1182/blood.2023020619.
    >> Share

  112. MELNICK AF, Mullin C, Lin K, McCarter AC, et al
    Cdc73 protects Notch-induced T-cell leukemia cells from DNA damage and mitochondrial stress.
    Blood. 2023 Aug 24:blood.2023020144. doi: 10.1182/blood.2023020144.
    >> Share

  113. PAGANI IS, Shanmuganathan N, Dang P, Saunders VA, et al
    Lineage-specific detection of residual disease predicts relapse in chronic myeloid leukemia patients stopping therapy.
    Blood. 2023 Aug 24:blood.2023021119. doi: 10.1182/blood.2023021119.
    >> Share

  114. RABIN KR
    Insights into the genomics of iAMP21-ALL.
    Blood. 2023;142:682-684.
    >> Share

  115. NIEMANN CU
    BTK inhibitors: safety + efficacy = outcome.
    Blood. 2023;142:679-680.
    >> Share

  116. MOLTENI E, Bono E, Galli A, Elena C, et al
    Prevalence and clinical expression of germ line predisposition to myeloid neoplasms in adults with marrow hypocellularity.
    Blood. 2023;142:643-657.
    >> Share

  117. SEZAKI M, Huang G
    Food for thought (and CML survival).
    Blood. 2023;142:502-504.
    >> Share

  118. MULLIGAN SP
    Karyotype and outcome in CLL.
    Blood. 2023;142:402-404.
    >> Share


  119. Moujalled DM, Brown FC, Chua CC, et al. Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia. Blood. 2023;141(6):634-644.
    Blood. 2023;142:494.
    >> Share


  120. Gaudio E, Paduano F, Ngankeu A, et al. Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas. Blood. 2013;121(2):351-359.
    Blood. 2023;142:495.
    >> Share

  121. SENJO H, Harada S, Kubota SI, Tanaka Y, et al
    Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT.
    Blood. 2023;142:477-492.
    >> Share

  122. FURSTENAU M, Thus YJ, Robrecht S, Mellink CHM, et al
    High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
    Blood. 2023;142:446-459.
    >> Share

  123. KHALSA JK, Cha J, Utro F, Naeem A, et al
    Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples.
    Blood. 2023;142:421-433.
    >> Share

    July 2023
  124. KOLIJN PM, Spath F, Khouja M, Hengeveld PJ, et al
    Genetic drivers in the natural history of chronic lymphocytic leukemia development as early as 16 years before diagnosis.
    Blood. 2023 Jul 31:blood.2023019609. doi: 10.1182/blood.2023019609.
    >> Share

  125. SCHIMMER AD
    ZDHHC21: a mitochondrial vulnerability in AML.
    Blood. 2023;142:309-311.
    >> Share

  126. GOTTHARDT D
    Targeting iron import to treat ANKL.
    Blood. 2023;142:308-309.
    >> Share

  127. MORGAN KM, Sojitra P
    Auer rod-like inclusions in chronic lymphocytic leukemia.
    Blood. 2023;142:397.
    >> Share

  128. SHAO X, Xu A, Du W, Xu T, et al
    The palmitoyltransferase ZDHHC21 regulates oxidative phosphorylation to induce differentiation block and stemness in AML.
    Blood. 2023;142:365-381.
    >> Share

  129. BOTTEN GA, Zhang Y, Dudnyk K, Kim YJ, et al
    Structural variation cooperates with permissive chromatin to control enhancer hijacking-mediated oncogenic transcription.
    Blood. 2023;142:336-351.
    >> Share

  130. GRAMATGES MM
    Poverty and health equity in childhood leukemia.
    Blood. 2023;142:211-212.
    >> Share

  131. VELOSO A, Cools J
    Targeting STAT5B in T-cell acute lymphoblastic leukemia.
    Blood. 2023;142:215-217.
    >> Share

  132. VADAKEKOLATHU J, Rutella S
    Escape from T-cell targeting immunotherapies in acute myeloid leukemia.
    Blood. 2023 Jul 19:blood.2023019961. doi: 10.1182/blood.2023019961.
    >> Share

  133. SENAPATI J, Urrutia S, Loghavi S, Short NJ, et al
    Venetoclax Abrogates the Prognostic Impact of Splicing Factor Gene Mutations in Newly Diagnosed Acute Myeloid Leukemia.
    Blood. 2023 Jul 13:blood.2023020649. doi: 10.1182/blood.2023020649.
    >> Share

  134. FRIES C, Hermiston ML
    Challenging T-ALL to IL-7Rp dual inhibition.
    Blood. 2023;142:124-126.
    >> Share

  135. GU Z, Izraeli S
    All about Down syndrome ALL.
    Blood. 2023;142:126-128.
    >> Share

  136. DEL BUFALO F, Becilli M, Rosignoli C, De Angelis B, et al
    Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL.
    Blood. 2023;142:146-157.
    >> Share

  137. GRIBBEN JG
    Targeting the methylome to improve CLL outcome.
    Blood. 2023;142:4-6.
    >> Share

  138. HODSON DJ
    Breaking the loop in AML.
    Blood. 2023;142:6-7.
    >> Share

  139. TORABI A, Naresh KN
    T-cell prolymphocytic leukemia/lymphoma with TCRB::TCL1 translocation.
    Blood. 2023;142:119.
    >> Share

  140. BAMEZAI S, Pulikkottil AJ, Yadav T, Vegi NM, et al
    A noncanonical enzymatic function of PIWIL4 maintains genomic integrity and leukemic growth in AML.
    Blood. 2023;142:90-105.
    >> Share

  141. PARRY EM, Ten Hacken E, Wu CJ
    Richter syndrome: novel insights into the biology of transformation.
    Blood. 2023;142:11-22.
    >> Share

    June 2023
  142. SEYMOUR JF, Byrd JC, Ghia P, Kater AP, et al
    Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in ELEVATE-RR.
    Blood. 2023 Jun 30:blood.2022018818. doi: 10.1182/blood.2022018818.
    >> Share

  143. ROY N, Park CY
    IL-34: a novel differentiation therapy for AML?
    Blood. 2023;141:3130-3132.
    >> Share

  144. KUPPERS R
    Targeting mRNA translation in CLL.
    Blood. 2023;141:3129-3130.
    >> Share


  145. Itzykson R, Fournier E, Berthon C, et al. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood. 2021;138(7):507-519.
    Blood. 2023;141:3233.
    >> Share


  146. Robin M, de Wreede LC, Padron E, et al. Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis. Blood. 2022;140(12):1408-1418.
    Blood. 2023;141:3232-3233.
    >> Share

  147. THOMPSON PA, Tam CS
    Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders.
    Blood. 2023;141:3137-3142.
    >> Share

  148. LARGEOT A, Klapp V, Viry E, Gonder S, et al
    Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as a therapeutic strategy in CLL.
    Blood. 2023;141:3166-3183.
    >> Share

  149. BRAMMER JE, Ballen K, Sokol L, Querfeld C, et al
    Effective Treatment with the Selective Cytokine Inhibitor BNZ-1 Reveals the Cytokine Dependency of T-LGL Leukemia.
    Blood. 2023 Jun 23:blood.2022017643. doi: 10.1182/blood.2022017643.
    >> Share

  150. STEEL K, Jamieson C
    Getting to the core of ADAR2 activity in AML.
    Blood. 2023;141:3014-3015.
    >> Share

  151. GUO M, Chan THM, Zhou Q, An O, et al
    Core-binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis.
    Blood. 2023;141:3078-3090.
    >> Share

  152. YOSIFOV DY, Stilgenbauer S
    Richter transformation: epigenetics to blame?
    Blood. 2023;141:2915-2917.
    >> Share

  153. LAM WK, Yip SF
    Cytopenic AML with marrow fibrosis and multihit TP53 abnormalities.
    Blood. 2023;141:3006.
    >> Share

  154. TSAGIOPOULOU M, Chapaprieta V, Russinol N, Garcia-Torre B, et al
    Chromatin activation profiling of stereotyped chronic lymphocytic leukemias reveals a subset 8-specific signature.
    Blood. 2023;141:2955-2960.
    >> Share

  155. BRAMLETT C, Eerdeng J, Jiang D, Lee Y, et al
    RNA splicing factor Rbm25 underlies heterogeneous preleukemic clonal expansion in mice.
    Blood. 2023;141:2961-2972.
    >> Share

  156. GUOLLA L, Breitbart S, Foroutan F, Thabane L, et al
    Impact of vincristine-steroid pulses during maintenance for B-cell pediatric ALL: a systematic review and meta-analysis.
    Blood. 2023;141:2944-2954.
    >> Share

  157. WLODARSKI MW
    ERCC6L2 syndrome: attack of the TP53 clones.
    Blood. 2023;141:2788-2789.
    >> Share

  158. EL CHAER F, Hourigan CS, Zeidan AM
    How I treat AML incorporating the updated classifications and guidelines.
    Blood. 2023;141:2813-2823.
    >> Share

  159. ROSS DM
    Single cells tell multiple tales in CML.
    Blood. 2023;141:2668-2670.
    >> Share

    May 2023
  160. TARIQ H, Davis A
    Pediatric mixed phenotype acute leukemia, T/myeloid, with isolated FLT3 mutation.
    Blood. 2023;141:2663.
    >> Share

  161. KIM MY
    CXCR4 to improve both T cell homing and function.
    Blood. 2023;141:2546-2547.
    >> Share

  162. GAO Q, Ryan SL, Iacobucci I, Ghate PS, et al
    The genomic landscape of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21.
    Blood. 2023 May 22:blood.2022019094. doi: 10.1182/blood.2022019094.
    >> Share


  163. Trinh BQ, Ummarino S, Zhang Y, et al. Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML. Blood. 2021;138(15):1331-1344.
    Blood. 2023;141:2542.
    >> Share

  164. QIU S, Sheth VS, Yan C, Liu J, et al
    Metabolic Adaptation to Tyrosine Kinase Inhibition in Leukemia Stem Cells.
    Blood. 2023 May 16:blood.2022018196. doi: 10.1182/blood.2022018196.
    >> Share

  165. CHANG Y, Keramatnia F, Ghate PS, Nishiguchi G, et al
    The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia.
    Blood. 2023 May 12:blood.2022017813. doi: 10.1182/blood.2022017813.
    >> Share

  166. WANG M
    Targeting leukemia with a metabolic genotoxin.
    Blood. 2023;141:2293-2295.
    >> Share

  167. DIAMOND B, Ziccheddu B, Maclachlan K, Taylor J, et al
    Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures.
    Blood. 2023;141:2359-2371.
    >> Share

  168. KAMEDA K, Yanagiya R, Miyatake Y, Carreras J, et al
    Hepatic niche leads to aggressive natural killer cell leukemia proliferation through transferrin-transferrin receptor 1 axis.
    Blood. 2023 May 5:blood.2022018597. doi: 10.1182/blood.2022018597.
    >> Share

  169. LEBECQUE B, Dannus LT
    BCOR/BCORL1 mutated hypergranular cells mimicking acute promyelocytic leukemia.
    Blood. 2023;141:2283.
    >> Share

  170. HUANG BJ, Shannon K
    NFIA-ETO2, TP53, and erythroid leukemogenesis.
    Blood. 2023;141:2168-2170.
    >> Share

  171. NIEMANN CU
    Immediate COVID-19 treatment in CLL.
    Blood. 2023;141:2167-2168.
    >> Share

  172. WEINBERG OK, Arber DA, Dohner H, Mullighan CG, et al
    The International Consensus Classification of acute leukemias of ambiguous lineage.
    Blood. 2023;141:2275-2277.
    >> Share

    April 2023
  173. LAMBLE AJ, Hagiwara K, Gerbing RB, Smith JL, et al
    CREBBP alterations are associated with a poor prognosis in de novo AML.
    Blood. 2023;141:2156-2159.
    >> Share

  174. WADHWA A, Chen Y, Hageman L, Hoppmann A, et al
    Poverty and Relapse Risk in Children with Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL03N1 Report.
    Blood. 2023 Apr 17:blood.2023019631. doi: 10.1182/blood.2023019631.
    >> Share

  175. RIBERA JM
    T-ALL in CNS-3 status needs improvement.
    Blood. 2023;141:1779-1780.
    >> Share

  176. USTUN C
    Gold is gold even in mud: NPM1 mutations in T-AML.
    Blood. 2023;141:1784-1785.
    >> Share

  177. WANG D, Sun Z, Zhu X, Zheng X, et al
    Wang D, Sun Z, Zhu X, et al. GARP-mediated active TGF-beta1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT. Blood. 2022;140(26):2788-2804.
    Blood. 2023;141:1896.
    >> Share


  178. Stein EM. IDH2 inhibition in AML. Blood. 2023;141(2):124-125.
    Blood. 2023;141:1896.
    >> Share

  179. PENTER L, Liu Y, Wolff JO, Yang L, et al
    Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.
    Blood. 2023;141:1817-1830.
    >> Share

  180. OTHMAN J, Meggendorfer M, Tiacci E, Thiede C, et al
    Overlapping features of therapy-related and de novo NPM1-mutated AML.
    Blood. 2023;141:1846-1857.
    >> Share

  181. GARCIA JS, Flamand Y, Penter L, Keng M, et al
    Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naive settings.
    Blood. 2023;141:1884-1888.
    >> Share

  182. JIANG Q, Stachelscheid J, Bloehdorn J, Pacholewska A, et al
    Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia.
    Blood. 2023 Apr 6:blood.2022017230. doi: 10.1182/blood.2022017230.
    >> Share

  183. COURTOIS L, Cabannes-Hamy A, Kim R, Delecourt M, et al
    IL7-receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK-inhibition.
    Blood. 2023 Apr 6:blood.2022017948. doi: 10.1182/blood.2022017948.
    >> Share

  184. FALINI B, Lazzi S
    B-cell prolymphocytic leukemia after COVID-19 infection.
    Blood. 2023;141:1777.
    >> Share


  185. Bewersdorf JP, Patel KK, Goshua G, et al. Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia. Blood. 2022;139(11):1766-1770.
    Blood. 2023;141:1778.
    >> Share

  186. DESHPANDE AJ, Zhu N
    Silencing with SAFB: a new role for HOXA9 in AML.
    Blood. 2023;141:1653-1655.
    >> Share

  187. BORNHAUSER M
    T cells reloaded after allogeneic HCT.
    Blood. 2023;141:1652-1653.
    >> Share

  188. DOLINSKA M, Cai H, Mansson A, Shen J, et al
    Characterization of Bone Marrow Niche in Chronic Myeloid Leukemia Patients Identifies CXCL14 as a New Therapeutic Option.
    Blood. 2023 Apr 5:blood.2022016896. doi: 10.1182/blood.2022016896.
    >> Share

  189. SI LIM S, Ford JB, Hermiston ML
    How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults.
    Blood. 2023 Apr 5:blood.2022016503. doi: 10.1182/blood.2022016503.
    >> Share

  190. ANJOS-AFONSO F, Bonnet D
    Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?
    Blood. 2023 Apr 5:blood.2022018071. doi: 10.1182/blood.2022018071.
    >> Share

    March 2023
  191. LI Z, Chang TC, Junco JJ, Devidas M, et al
    Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia.
    Blood. 2023 Mar 31:blood.2023019765. doi: 10.1182/blood.2023019765.
    >> Share

  192. XIE X, Zhang W, Xiao M, Wei T, et al
    TREM2 acts as a receptor for IL-34 to suppress acute myeloid leukemia in mice.
    Blood. 2023 Mar 31:blood.2022018619. doi: 10.1182/blood.2022018619.
    >> Share

  193. HELMAN SR, Singh ZN
    B-acute lymphoblastic leukemia with eosinophilic inclusions.
    Blood. 2023;141:1645.
    >> Share

  194. BROWN FC, Wei AH
    Is BCL-xL the Achilles' heel of AEL and AMKL?
    Blood. 2023;141:1505-1506.
    >> Share

  195. PORTELINHA A, Wendel HG
    The cat-and-mouse game of BTK inhibition.
    Blood. 2023;141:1502-1503.
    >> Share

  196. CALVO J, Pflumio F
    beta-Catenin and its new partner FOXO3 shake T-ALL.
    Blood. 2023;141:1503-1505.
    >> Share


  197. Bonfiglio F, Bruscaggin A, Guidetti F, et al. Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood. 2022;139(5):732-747.
    Blood. 2023;141:1647.
    >> Share

  198. MAKISHIMA H, Bowman TV, Godley LA
    DDX41-associated susceptibility to myeloid neoplasms.
    Blood. 2023;141:1544-1552.
    >> Share

  199. ZHANG D, Harris HM, Chen J, Judy J, et al
    NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts.
    Blood. 2023;141:1584-1596.
    >> Share

  200. TREMBLAY CS, Saw J, Boyle JA, Haigh K, et al
    STAT5 activation promotes progression and chemotherapy-resistance in early T-cell precursor acute lymphoblastic leukemia.
    Blood. 2023 Mar 29:blood.2022016322. doi: 10.1182/blood.2022016322.
    >> Share

  201. HAKKARAINEN M, Kaaja I, Douglas SPM, Vulliamy TJ, et al
    The Clinical Picture of the ERCC6L2 Disease - from Bone Marrow Failure to Acute Leukemia.
    Blood. 2023 Mar 23:blood.2022019425. doi: 10.1182/blood.2022019425.
    >> Share

  202. MEYER SE
    Context is key for FLT3-ITD.
    Blood. 2023;141:1373-1374.
    >> Share

  203. SAHASRABUDDHE AA, Elenitoba-Johnson KSJ
    TCL1A expression promotes aggressive biology in CLL.
    Blood. 2023;141:1371-1373.
    >> Share

  204. LI Y, Yang W, Patel RM, Casey EB, et al
    FLT3ITD drives context-specific changes in cell identity and variable interferon dependence during AML initiation.
    Blood. 2023;141:1442-1456.
    >> Share

  205. STACHELSCHEID J, Jiang Q, Aszyk C, Warner K, et al
    The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL.
    Blood. 2023;141:1425-1441.
    >> Share

  206. HEIMES DILLON AL, Kelting SM
    Aggressive mast cell leukemia/sarcoma with CD4 expression and hemophagocytosis.
    Blood. 2023;141:1364.
    >> Share


  207. Testi AM, Pession A, Diverio D, et al. Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. Blood. 2018;132(4):405-412.
    Blood. 2023;141:1365.
    >> Share


  208. Lew TE, Tam CS, Seymour JF. How I treat chronic lymphocytic leukemia after venetoclax. Blood. 2021;138(5):361-369.
    Blood. 2023;141:1366.
    >> Share

  209. SIMONIN M, Andrieu GP, Birsen R, Balsat M, et al
    Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL.
    Blood. 2023;141:1353-1358.
    >> Share

  210. SCHNEGG-KAUFMANN AS, Thoms JAI, Bhuyan GS, Hampton HR, et al
    Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy.
    Blood. 2023;141:1316-1321.
    >> Share

  211. DAVER NG, Dail M, Garcia JS, Jonas BA, et al
    Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
    Blood. 2023;141:1265-1276.
    >> Share

  212. NGAI LL, Hanekamp D, Janssen F, Carbaat-Ham J, et al
    Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial.
    Blood. 2023 Mar 10:blood.2022019160. doi: 10.1182/blood.2022019160.
    >> Share

  213. CHIHARA D
    Synthetic lethality in ATL.
    Blood. 2023;141:1096-1098.
    >> Share

  214. SMITH M
    Harnessing ADR T cells to enhance allo-HCT.
    Blood. 2023;141:1101-1102.
    >> Share

  215. GREVER MR
    Two-inhibitor salvage therapy for hairy cell leukemia.
    Blood. 2023;141:965-966.
    >> Share

  216. PFLUG N
    T-LGLL: variety is the spice of this leukemia.
    Blood. 2023;141:967-969.
    >> Share

  217. HIWASE D, Hahn C, Tran ENH, Chhetri R, et al
    TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype.
    Blood. 2023;141:1087-1091.
    >> Share

  218. PERIS I, Romero-Murillo S, Martinez-Balsalobre E, Farrington CC, et al
    Activation of the PP2A-B56alpha heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation.
    Blood. 2023;141:1047-1059.
    >> Share

  219. ROAS M, Vick B, Kasper MA, Able M, et al
    Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML.
    Blood. 2023;141:1023-1035.
    >> Share

  220. KRISHNAN V, Schmidt F, Nawaz Z, Venkatesh PN, et al
    A Single-cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid Leukemia.
    Blood. 2023 Mar 1:blood.2022017295. doi: 10.1182/blood.2022017295.
    >> Share

    February 2023
  221. TADMOR T, Alapi H, Rokach L
    Effectiveness of nirmatrelvir plus ritonavir treatment for patients with CLL during the Omicron Surge.
    Blood. 2023 Feb 27:blood.2022019017. doi: 10.1182/blood.2022019017.
    >> Share

  222. GHALANDARY M, Gao Y, Amend D, Kutkaite G, et al
    WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice.
    Blood. 2023;141:955-960.
    >> Share

  223. BANGHAM CRM
    HTLV-1 persistence and the oncogenesis of adult T cell leukemia/lymphoma.
    Blood. 2023 Feb 17:blood.2022019332. doi: 10.1182/blood.2022019332.
    >> Share

  224. COLOM DIAZ PA, Mistry JJ, Trowbridge JJ
    Hematopoietic Stem Cell Aging and Leukemia Transformation.
    Blood. 2023 Feb 17:blood.2022017933. doi: 10.1182/blood.2022017933.
    >> Share


  225. Hsu CA, Rishi AK, Su-Li X, et al. Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor-independent pathway. Blood. 1997;89(12):4470-4479.
    Blood. 2023;141:808.
    >> Share

  226. JIMENEZ A, Shuai W
    BRAF-negative, CD103-negative hairy cell leukemia.
    Blood. 2023;141:806.
    >> Share

  227. LENGLINE E
    C1q helps AML to disseminate and resist.
    Blood. 2023;141:691-692.
    >> Share

  228. RIBERA JM
    JZP458 closes the asparaginase allergy gap.
    Blood. 2023;141:685-686.
    >> Share

  229. ELITZUR S, Vora A, Burkhardt B, Inaba H, et al
    EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy.
    Blood. 2023;141:743-755.
    >> Share

  230. BIONDI M, Tettamanti S, Galimberti S, Cerina B, et al
    Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the Acute Myeloid Leukemia burden.
    Blood. 2023 Feb 14:blood.2022018330. doi: 10.1182/blood.2022018330.
    >> Share

  231. KIM WJ, Abdel-Wahab O
    Acquired BAX mutations in AML.
    Blood. 2023;141:562-564.
    >> Share

  232. NEWMAN H, Li Y, Liu H, Myers RM, et al
    Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy.
    Blood. 2023;141:609-619.
    >> Share

  233. PATTERSON MT, Khan SM, Nunes NS, Fletcher RE, et al
    Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects.
    Blood. 2023;141:659-672.
    >> Share

  234. PIQUE-BORRAS MR, Jevtic Z, Otzen Bagger F, Seguin J, et al
    The NFIA-ETO2 fusion blocks erythroid maturation and induces pure erythroid leukemia in cooperation with mutant TP53.
    Blood. 2023 Feb 3:blood.2022017273. doi: 10.1182/blood.2022017273.
    >> Share

  235. LOPEZ CK, Mercher T
    ERGonomics for EVI1 acute myeloid leukemia.
    Blood. 2023;141:441-443.
    >> Share

  236. TRUONG P, Pimanda JE
    DDX41: the poster child for familial MDS/AML grows up.
    Blood. 2023;141:447-449.
    >> Share

  237. FERRERO S, Genuardi E
    Looking for a needle in the haystack of CLL.
    Blood. 2023;141:445-447.
    >> Share

  238. IYER SP
    Newer insights on how to TEC down T-ALL.
    Blood. 2023;141:444-445.
    >> Share

  239. MAKISHIMA H, Saiki R, Nannya Y, Korotev S, et al
    Germ line DDX41 mutations define a unique subtype of myeloid neoplasms.
    Blood. 2023;141:534-549.
    >> Share

  240. SVATON M, Skotnicova A, Reznickova L, Rennerova A, et al
    NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol.
    Blood. 2023;141:529-533.
    >> Share

  241. SCHMOELLERL J, Barbosa IAM, Minnich M, Andersch F, et al
    EVI1 drives leukemogenesis through aberrant ERG activation.
    Blood. 2023;141:453-466.
    >> Share

  242. HENGEVELD PJ, van der Klift MY, Kolijn PM, Davi F, et al
    Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL.
    Blood. 2023;141:519-528.
    >> Share

    January 2023
  243. TAHIR SK, Calvo E, Carnero BA, Yuda J, et al
    Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia.
    Blood. 2023 Jan 30:blood.2022017333. doi: 10.1182/blood.2022017333.
    >> Share

  244. ANGENENDT L, Rollig C, Montesinos P, Ravandi F, et al
    Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification.
    Blood. 2023;141:433-435.
    >> Share

  245. STURGESS KHM, Wilson NK, Gottgens B
    Introduction to a review series on single-cell genomics: getting ready for clinical impact in leukemia and myeloid neoplasms.
    Blood. 2023;141:323-325.
    >> Share

  246. EDIRIWICKREMA A, Gentles AJ, Majeti R
    Single-cell genomics in AML: extending the frontiers of AML research.
    Blood. 2023;141:345-355.
    >> Share

  247. GANSER A
    Role of allotransplantation in older patients with AML.
    Blood. 2023;141:217-218.
    >> Share

  248. OLIVA-ARIZA G, Fuentes-Herrero B, Carbonell C, Lecrevisse Q, et al
    High frequency of low-count monoclonal B-cell lymphocytosis in hospitalized COVID-19 patients.
    Blood. 2023;141:309-314.
    >> Share

  249. LEE BC, Zhou Y, Bresciani E, Ozkaya N, et al
    A RUNX1-FPDMM rhesus macaque model reproduces the human phenotype and predicts challenges to curative gene therapies.
    Blood. 2023;141:231-237.
    >> Share

  250. SORROR ML, Gooley TA, Storer BE, Gerds AT, et al
    An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML.
    Blood. 2023;141:295-308.
    >> Share

  251. CHEN H, Bai Y, Kobayashi M, Xiao S, et al
    PRL2 phosphatase enhances oncogenic FLT3 signaling via dephosphorylation of the E3 ubiquitin ligase CBL at tyrosine 371.
    Blood. 2023;141:244-259.
    >> Share

  252. DE BOTTON S, Montesinos P, Schuh AC, Papayannidis C, et al
    Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
    Blood. 2023;141:156-167.
    >> Share

  253. STEIN EM
    IDH2 inhibition in AML.
    Blood. 2023;141:124-125.
    >> Share

  254. RATTIGAN KM, Zarou MM, Helgason V
    Metabolism in stem cell driven leukaemia: parallels between haematopoiesis and immunity.
    Blood. 2023 Jan 12:blood.2022018258. doi: 10.1182/blood.2022018258.
    >> Share

  255. GOSSAI N, Devidas M, Chen Z, Wood BL, et al
    Central Nervous System Status is Prognostic in T-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report.
    Blood. 2023 Jan 5:blood.2022018653. doi: 10.1182/blood.2022018653.
    >> Share

  256. HEUCHON M, Wiber M
    Cuplike nuclei in B-cell acute lymphoblastic leukemia with DUX4 rearrangement.
    Blood. 2023;141:121.
    >> Share

  257. FRIEND BD
    Treatment intensity in AML: a double-edged sword.
    Blood. 2023;141:5-7.
    >> Share

  258. TURCOTTE LM, Whitton JA, Leisenring WM, Howell RM, et al
    Chronic conditions, late mortality, and health status after childhood AML: a Childhood Cancer Survivor Study report.
    Blood. 2023;141:90-101.
    >> Share

  259. CLARKE ML, Lemma RB, Walton DS, Volpe G, et al
    MYB insufficiency disrupts proteostasis in hematopoietic stem cells leading to age-related neoplasia.
    Blood. 2023 Jan 5:blood.2022019138. doi: 10.1182/blood.2022019138.
    >> Share

  260. MOES B, Li H, Molina-Ortiz P, Radermecker C, et al
    INPP5K controls the dynamic structure and signaling of wild type and mutated, leukemia-associated IL7 receptors.
    Blood. 2023 Jan 4:blood.2022017819. doi: 10.1182/blood.2022017819.
    >> Share

    December 2022
  261. VEKARIYA U, Toma MM, Nieborowska-Skorska M, Le BV, et al
    DNA polymerase theta protects leukemia cells from metabolic-induced DNA damage.
    Blood. 2022 Dec 29:blood.2022018428. doi: 10.1182/blood.2022018428.
    >> Share

  262. KIM S, Choi J
    Restoring NK cell functions in AML relapse.
    Blood. 2022;140:2765-2766.
    >> Share

  263. WANG D, Sun Z, Zhu X, Zheng X, et al
    GARP-mediated active TGF-beta1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT.
    Blood. 2022;140:2788-2804.
    >> Share

  264. AGRAWAL-SINGH S, Bagri J, Giotopoulos G, Azazi D, et al
    HOXA9 forms a repressive complex with nuclear matrix-associated protein SAFB to maintain acute myeloid leukemia.
    Blood. 2022 Dec 28:blood.2022016528. doi: 10.1182/blood.2022016528.
    >> Share

  265. RIMANDO JC, Chendamarai E, Rettig MP, Jayasinghe RG, et al
    Flotetuzumab and other T-Cell Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells.
    Blood. 2022 Dec 23:blood.2022017795. doi: 10.1182/blood.2022017795.
    >> Share

  266. MISHRA SK, Millman SE, Zhang L
    Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets.
    Blood. 2022 Dec 22:blood.2022018092. doi: 10.1182/blood.2022018092.
    >> Share

  267. KOPMAR NE, Cassaday R
    How I Prevent and Treat Central Nervous System Disease in Adults with Acute Lymphoblastic Leukemia.
    Blood. 2022 Dec 22:blood.2022017035. doi: 10.1182/blood.2022017035.
    >> Share

  268. DEARDEN C
    It's a BRAF new world for hairy cell leukemia.
    Blood. 2022;140:2649-2650.
    >> Share

  269. MELLINGHOFF SC, Cornely OA
    SARS-CoV-2 vaccination in CLL: how often is enough?
    Blood. 2022;140:2655-2657.
    >> Share

  270. SHEN Y, Freeman JA, Holland J, Naidu K, et al
    Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion.
    Blood. 2022;140:2709-2721.
    >> Share

  271. WEI AH, Panayiotidis P, Montesinos P, Laribi K, et al
    Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy.
    Blood. 2022;140:2754-2756.
    >> Share

  272. FREIWAN A, Zoine JT, Crawford JC, Vaidya A, et al
    Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies.
    Blood. 2022;140:2684-2696.
    >> Share

  273. BERTAINA A
    Believe in haploidentical HSCT: less is better.
    Blood. 2022;140:2523-2524.
    >> Share

  274. BRAUN T
    An unexpected partnership targeting FLT3wt AML.
    Blood. 2022;140:2529-2530.
    >> Share

  275. PULSIPHER MA, Ahn KW, Bunin NJ, Lalefar N, et al
    KIR-favorable TCR-alphabeta/CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trial.
    Blood. 2022;140:2556-2572.
    >> Share

  276. KUUSANMAKI H, Dufva O, Vaha-Koskela M, Leppa AM, et al
    Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.
    Blood. 2022 Dec 12:blood.2021011094. doi: 10.1182/blood.2021011094.
    >> Share

  277. GIALESAKI S, Brauer-Hartmann D, Issa H, Bhayadia R, et al
    RUNX1 isoform disequilibrium promotes the development of trisomy 21 associated myeloid leukemia.
    Blood. 2022 Dec 9:blood.2022017619. doi: 10.1182/blood.2022017619.
    >> Share

  278. PRZESPOLEWSKI A, Goldberg AD, Talati C, Fazal S, et al
    Safety and efficacy of CPX-351 in younger patients (< 60 years) with secondary acute myeloid leukemia.
    Blood. 2022 Dec 9:blood.2022016678. doi: 10.1182/blood.2022016678.
    >> Share

  279. ZAHID MF, Kainthla R
    Dinner-plate nuclei in hypogranular acute promyelocytic leukemia.
    Blood. 2022;140:2519.
    >> Share

  280. RAHNAMA R, Bonifant CL
    Engineering builds multipotency for iPSC-NKs.
    Blood. 2022;140:2414-2416.
    >> Share

  281. CHIATTONE C, Alencar AJ
    A balancing act between toxicity and deep response.
    Blood. 2022;140:2309-2311.
    >> Share

  282. WANG QF, Zhu HH
    APL: Nemo finds its sea anemone.
    Blood. 2022;140:2311-2312.
    >> Share

  283. BLIXT L, Gao Y, Wullimann D, Muren Ingelman-Sundberg H, et al
    Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination.
    Blood. 2022;140:2403-2407.
    >> Share

  284. MARTINES C, Chakraborty S, Vujovikj M, Gobessi S, et al
    Macrophage- and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo.
    Blood. 2022;140:2335-2347.
    >> Share

  285. POPLINEAU M, Platet N, Mazuel A, Herault L, et al
    Noncanonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias.
    Blood. 2022;140:2358-2370.
    >> Share

  286. LOO S, Dillon R, Ivey A, Anstee NS, et al
    Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome.
    Blood. 2022;140:2407-2411.
    >> Share

  287. SCARFO L, Heltai S, Albi E, Scarano E, et al
    Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL.
    Blood. 2022;140:2348-2357.
    >> Share

    November 2022
  288. CHITADZE G, Stengel A, John-Klaua C, Bruckmuller J, et al
    Somatic TP53 mutations are pre-leukemic events in acute lymphoblastic leukemia.
    Blood. 2022 Nov 30:blood.2022017249. doi: 10.1182/blood.2022017249.
    >> Share

  289. GHOBADI A, Slade M, Kantarjian H, Alvarenga J, et al
    The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis.
    Blood. 2022;140:2101-2112.
    >> Share

  290. THIJSSEN R, Tian L, Anderson MA, Flensburg C, et al
    Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy.
    Blood. 2022;140:2127-2141.
    >> Share

  291. THOMALLA D, Beckmann L, Grimm C, Oliverio M, et al
    Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.
    Blood. 2022;140:2113-2126.
    >> Share

  292. DORES GM, Linet MS, Curtis RE, Morton LM, et al
    Risks of therapy-related hematologic neoplasms beyond myelodysplastic syndromes and acute myeloid leukemia.
    Blood. 2022 Nov 15. pii: 493239. doi: 10.1182/blood.2022018051.
    >> Share

  293. GALLIPOLI P
    AML gets upSET when its dietary needs are unMet.
    Blood. 2022;140:2003-2004.
    >> Share

  294. MURPHY WJ
    Giving alloHSCT a needed LIF(t).
    Blood. 2022;140:2008-2009.
    >> Share

  295. CHIBA M, Shimono J, Ishio T, Takei N, et al
    Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas.
    Blood. 2022;140:1951-1963.
    >> Share

  296. YANG LX, Zhang CT, Yang MY, Zhang XH, et al
    C1Q labels a highly aggressive macrophage-like leukemia population indicating extramedullary infiltration and relapse.
    Blood. 2022 Nov 2. pii: 486969. doi: 10.1182/blood.2022017046.
    >> Share

    October 2022
  297. PANELLI P, De Santis E, Colucci M, Tamiro F, et al
    Noncanonical beta-catenin interactions promote leukemia-initiating activity in early T-cell acute lymphoblastic leukemia.
    Blood. 2022 Oct 31. pii: 486952. doi: 10.1182/blood.2022017079.
    >> Share

  298. IACOBUCCI I, Mullighan CG
    KMT2A-rearranged leukemia: the shapeshifter.
    Blood. 2022;140:1833-1835.
    >> Share

  299. AL-ATTAR A, Woda BA
    kappa light chain-expressing hematogones in a patient with lambda-restricted CLL and multiple myeloma on daratumumab therapy.
    Blood. 2022;140:1917.
    >> Share

  300. WANG ES, Montesinos P, Minden MD, Lee JH, et al
    Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
    Blood. 2022;140:1845-1857.
    >> Share

  301. TIRTAKUSUMA R, Szoltysek K, Milne P, Grinev VV, et al
    Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia.
    Blood. 2022;140:1875-1890.
    >> Share

  302. SHARMA M, Fu MP, Lu HY, Sharma AA, et al
    Human complete NFAT1 deficiency causes a triad of joint contractures, osteochondromas, and B-cell malignancy.
    Blood. 2022;140:1858-1874.
    >> Share

  303. ZHAO L, Li S, Wei X, Qi X, et al
    A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL.
    Blood. 2022;140:1790-1802.
    >> Share

  304. MARTI G
    The clonal evolution and natural history of MBL.
    Blood. 2022;140:1660-1661.
    >> Share

  305. SLAGER SL, Parikh SA, Achenbach SJ, Norman AD, et al
    Progression and survival of MBL: a screening study of 10 139 individuals.
    Blood. 2022;140:1702-1709.
    >> Share

  306. DOHNER H, Wei AH, Roboz GJ, Montesinos P, et al
    Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
    Blood. 2022;140:1674-1685.
    >> Share

  307. MOUJALLED DM, Brown FC, Chua CC, Dengler MA, et al
    Acquired mutations in BAX confer resistance to BH3-mimetic therapy in Acute Myeloid Leukemia.
    Blood. 2022 Oct 11. pii: 486781. doi: 10.1182/blood.2022016090.
    >> Share

  308. KIPPS TJ
    ROR1: an orphan becomes apparent.
    Blood. 2022;140:1583-1591.
    >> Share

    September 2022
  309. RYLAND G, Umeda M, Holmfeldt L, Lehmann S, et al
    Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions.
    Blood. 2022 Sep 30. pii: 486718. doi: 10.1182/blood.2022017874.
    >> Share

  310. BERNT KM
    Do you need the immune system to cure ALL?
    Blood. 2022;140:1457-1458.
    >> Share


  311. Freeman SD, Valk P. Transplant in older adults with AML: genomic wheat and chaff. Blood. 2022;139(24):3459-3461.
    Blood. 2022;140:1571.
    >> Share

  312. VAISITTI T, Vitale N, Micillo M, Brandimarte L, et al
    Anti-CD37 alpha-amanitin-conjugated antibodies as potential therapeutic weapons for Richter syndrome.
    Blood. 2022;140:1565-1569.
    >> Share

  313. IZUTSU K, Makita S, Nosaka K, Yoshimitsu M, et al
    An Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma.
    Blood. 2022 Sep 23. pii: 486703. doi: 10.1182/blood.2022016862.
    >> Share

  314. SCHILLER G
    How thinly can one slice the AML diagnostic pie?
    Blood. 2022;140:1330-1331.
    >> Share

  315. GUINIPERO T, Kahwash SB
    Morphologic findings often provide guidance when immunophenotypic data overlap: a case of AML with cup-shaped nuclei.
    Blood. 2022;140:1448.
    >> Share

  316. DOHNER H, Wei AH, Appelbaum FR, Craddock C, et al
    Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
    Blood. 2022;140:1345-1377.
    >> Share

  317. ZHANG M, Zhang H, Li Z, Bai L, et al
    Functional, structural, and molecular characterizations of the leukemogenic driver MEF2D-HNRNPUL1 fusion.
    Blood. 2022;140:1390-1407.
    >> Share

  318. DUNCAVAGE EJ, Bagg A, Hasserjian RP, DiNardo CD, et al
    Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia.
    Blood. 2022 Sep 21. pii: 486675. doi: 10.1182/blood.2022015853.
    >> Share

  319. KREITMAN RJ, Moreau P, Ravandi F, Hutchings M, et al
    Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.
    Blood. 2022 Sep 15. pii: 486621. doi: 10.1182/blood.2021013658.
    >> Share

  320. MAESE LD, Loh ML, Choi MR, Lin T, et al
    Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia: Results from the Phase 2/3 AALL1931 Study.
    Blood. 2022 Sep 15. pii: 486644. doi: 10.1182/blood.2022016923.
    >> Share

  321. PENTER L, Wu CJ
    AML relapse after a TIGIT race.
    Blood. 2022;140:1189-1191.
    >> Share


  322. Duault C, Kumar A, Taghi Khani A, et al. Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia. Blood. 2021;138(16):1465-1480.
    Blood. 2022;140:1326-1327.
    >> Share

  323. BARILA' G, Grassi A, Cheon H, Teramo A, et al
    Tgammadelta LGL LEUKEMIA IDENTIFIES A SUBSET WITH MORE SYMPTOMATIC DISEASE: ANALYSIS OF AN INTERNATIONAL COHORT OF 137 PATIENTS.
    Blood. 2022 Sep 12. pii: 486580. doi: 10.1182/blood.2021013489.
    >> Share

  324. NAGLER A, Wu CJ
    The end of the beginning: Application of single cell sequencing to chronic lymphocytic leukemia (CLL).
    Blood. 2022 Sep 12. pii: 486574. doi: 10.1182/blood.2021014669.
    >> Share

  325. WU HC, de The H
    In APL, noncoding mutations and SNP converge on WT1.
    Blood. 2022;140:1060-1061.
    >> Share

  326. PHILIPP N, Kazerani M, Nicholls A, Vick B, et al
    T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.
    Blood. 2022;140:1104-1118.
    >> Share

    August 2022
  327. MO F, Watanabe N, Ingersoll Omdahl K, Burkhardt PM, et al
    Engineering T cells to suppress acute GvHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation.
    Blood. 2022 Aug 31. pii: 486464. doi: 10.1182/blood.2022016052.
    >> Share

  328. KITTAI AS, Woyach JA
    uMRD: "the" endpoint or "an" endpoint for CLL?
    Blood. 2022;140:797-798.
    >> Share

  329. OBENG EA
    Mutant SF3B1 splices a more leukemogenic EVI1.
    Blood. 2022;140:800-801.
    >> Share

  330. SEYMOUR JF, Kipps TJ, Eichhorst BF, D'Rozario J, et al
    Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
    Blood. 2022;140:839-850.
    >> Share

  331. CUNNINGHAM A, Erdem A, Alshamleh I, Geugien M, et al
    Dietary methionine starvation impairs acute myeloid leukemia progression.
    Blood. 2022 Aug 19. pii: 486352. doi: 10.1182/blood.2022017575.
    >> Share

  332. CAPPELLI LV, Fiore D, Phillip JM, Yoffe L, et al
    Endothelial-leukemia interactions remodel drug responses uncovering T-ALL vulnerabilities.
    Blood. 2022 Aug 18. pii: 486319. doi: 10.1182/blood.2022015414.
    >> Share

  333. WANG J, Chang CY, Yang X, Zhou F, et al
    Leukemia inhibitory factor protects against graft-versus-host disease while preserving graft-versus-leukemia activity.
    Blood. 2022 Aug 18. pii: 486317. doi: 10.1182/blood.2022015677.
    >> Share

  334. RIO-MACHIN A, Fitzgibbon J
    DDX41: the poster child for familial AML.
    Blood. 2022;140:667-669.
    >> Share

  335. LI P, Brown S, Williams M, White T, et al
    The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms.
    Blood. 2022;140:716-755.
    >> Share

  336. WAGNER DL
    The uncut version: base-edited allo-CAR T cells.
    Blood. 2022;140:526-527.
    >> Share

  337. DEAGLIO S
    Glutamine and CLL: ready for prime time?
    Blood. 2022;140:528-529.
    >> Share

  338. DIORIO C, Murray R, Naniong M, Barrera L, et al
    Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL.
    Blood. 2022;140:619-629.
    >> Share

  339. CARRATT SA, Kong GL, Curtiss BM, Schonrock Z, et al
    Mutated SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms.
    Blood. 2022;140:644-658.
    >> Share

  340. HANDA S, Lee JO, Derkach A, Stone RM, et al
    Long Term Outcomes in Patients with Relapsed or Refractory Hairy Cell Leukemia Treated with Vemurafenib Monotherapy.
    Blood. 2022 Aug 5. pii: 486128. doi: 10.1182/blood.2022016183.
    >> Share

  341. IACOBUCCI I, Witkowski MT, Mullighan CG
    Single-cell analysis of acute lymphoblastic and lineage ambiguous leukemia - approaches and molecular insights.
    Blood. 2022 Aug 4. pii: 486119. doi: 10.1182/blood.2022016954.
    >> Share

  342. VOSO MT, Buccisano F
    AML: making residual disease more measurable.
    Blood. 2022;140:415-417.
    >> Share

  343. SCARFO L, Herishanu Y
    CLL and COVID-19: light at the end of the tunnel?
    Blood. 2022;140:407-409.
    >> Share

  344. LI SQ, Xu LP, Wang Y, Zhang XH, et al
    An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study.
    Blood. 2022;140:516-520.
    >> Share

  345. SHALABI H, Qin H, Su A, Yates B, et al
    CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
    Blood. 2022;140:451-463.
    >> Share

  346. NIEMANN CU, da Cunha-Bang C, Helleberg M, Ostrowski SR, et al
    Patients with CLL have a lower risk of death from COVID-19 in the Omicron era.
    Blood. 2022;140:445-450.
    >> Share

  347. CICHOCKI F, Goodridge J, Bjordahl R, Mahmood S, et al
    Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia.
    Blood. 2022 Aug 2. pii: 486089. doi: 10.1182/blood.2021015184.
    >> Share

    July 2022
  348. VELASQUEZ MP, Mamonkin M
    CD7 CAR: sword and shield.
    Blood. 2022;140:293-294.
    >> Share

  349. GERDEMANN U, Alvarez-Calderon F
    Uncovering CD4+ T-cell exhaustion in B-ALL.
    Blood. 2022;140:294-296.
    >> Share

  350. LU P, Liu Y, Yang J, Zhang X, et al
    Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial.
    Blood. 2022;140:321-334.
    >> Share

  351. BLACK GS, Huang X, Qiao Y, Tarapcsak S, et al
    Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients.
    Blood. 2022;140:401-405.
    >> Share

  352. KRAMER MH, Zhang Q, Sprung R, Day RB, et al
    Proteomic and Phosphoproteomic Landscapes of Acute Myeloid Leukemia.
    Blood. 2022 Jul 27. pii: 486036. doi: 10.1182/blood.2022016033.
    >> Share

  353. ZEIDAN AM, Fenaux P, Gobbi M, Mayer J, et al
    Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy.
    Blood. 2022;140:285-289.
    >> Share

  354. HO JG, Schmidt D, Lowinus T, Ryoo J, et al
    Targeting MDM2 enhances anti-leukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation.
    Blood. 2022 Jul 19. pii: 485955. doi: 10.1182/blood.2022016082.
    >> Share

  355. EICHHORST B
    Ibrutinib frontline in young patients with CLL.
    Blood. 2022;140:80-81.
    >> Share

  356. XU K, Nacheva E
    Secondary AML with MLL gene amplification.
    Blood. 2022;140:161.
    >> Share

  357. SHANAFELT TD, Wang XV, Hanson CA, Paietta EM, et al
    Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
    Blood. 2022;140:112-120.
    >> Share

  358. JANSSEN M, Schmidt C, Bruch PM, Blank MF, et al
    Venetoclax synergizes with Gilteritinib in FLT3 wildtype high-risk Acute Myeloid Leukemia by suppressing MCL-1.
    Blood. 2022 Jul 13. pii: 485887. doi: 10.1182/blood.2021014241.
    >> Share

  359. GOURNAY V, Vallet N, Peux V, Vera K, et al
    Immune landscape after allo-HSCT: TIGIT and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse.
    Blood. 2022 Jul 12. pii: 485877. doi: 10.1182/blood.2022015522.
    >> Share

  360. DIORIO C, Teachey DT
    Please eat me! Targeting CD47 and CD38 in T-ALL.
    Blood. 2022;140:6-8.
    >> Share

  361. GOWER M, Tikhonova AN
    Avoiding fratricide: a T-ALL order.
    Blood. 2022;140:3-4.
    >> Share

  362. HASSERJIAN RP
    Revealing the dark secrets of TP53-mutated AML.
    Blood. 2022;140:8-10.
    >> Share

  363. MULLER K, Vogiatzi F, Winterberg D, Rosner T, et al
    Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL.
    Blood. 2022;140:45-57.
    >> Share

    June 2022
  364. THAKRAL B, Bueso-Ramos CE
    Unexpected presentation of cold agglutinin syndrome with B-acute lymphoblastic leukemia.
    Blood. 2022;139:3778.
    >> Share

  365. BARTH BM
    Ceramide: improving Bcl-2 inhibitor therapy.
    Blood. 2022;139:3676-3678.
    >> Share

  366. WANG H, He X, Zhang L, Dong H, et al
    Disruption of dNTP homeostasis by ribonucleotide reductase hyperactivation overcomes AML differentiation blockade.
    Blood. 2022;139:3752-3770.
    >> Share

  367. ARBER DA, Orazi A, Hasserjian RP, Borowitz MJ, et al
    International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data.
    Blood. 2022 Jun 29. pii: 485730. doi: 10.1182/blood.2022015850.
    >> Share

  368. QIU L, Quesada AE
    Plasma cell leukemia with small cell morphology.
    Blood. 2022;139:3667.
    >> Share


  369. Al-Sawaf O, Lilienweiss E, Bahlo J, et al. High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. Blood. 2020;135(11):866-870.
    Blood. 2022;139:3669.
    >> Share

  370. TANAKA A, Nakano TA, Nomura M, Yamazaki H, et al
    Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia.
    Blood. 2022 Jun 16. pii: 485590. doi: 10.1182/blood.2021015325.
    >> Share

  371. FIORETOS T
    Why B(-)other? About the gap of unknowns in ALL.
    Blood. 2022;139:3455-3457.
    >> Share

  372. FREEMAN SD, Valk P
    Transplant in older adults with AML: genomic wheat and chaff.
    Blood. 2022;139:3459-3461.
    >> Share


  373. Genetics and outcome in older AML transplant.
    Blood. 2022;139:3559.
    >> Share

  374. YEUNG DT, Shanmuganathan N, Hughes TP
    Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.
    Blood. 2022;139:3474-3479.
    >> Share

  375. PASSET M, Kim R, Gachet S, Sigaux F, et al
    Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL.
    Blood. 2022;139:3505-3518.
    >> Share

  376. MURDOCK HM, Kim HT, Denlinger N, Vachhani P, et al
    Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML.
    Blood. 2022;139:3546-3557.
    >> Share

  377. CHEMINANT M, Lhermitte L, Bruneau J, Sicard H, et al
    KIR3DL2 contributes to the typing of acute-type adult T-cell leukemia and is a potential therapeutic target.
    Blood. 2022 Jun 10. pii: 485527. doi: 10.1182/blood.2022016765.
    >> Share

  378. ALVAREZ S, da Silva Almeida AC, Albero R, Biswas M, et al
    Functional mapping of PHF6 complexes in chromatin remodeling, replication dynamics, and DNA repair.
    Blood. 2022;139:3418-3429.
    >> Share

  379. PERL AE, Larson RA, Podoltsev NA, Strickland S, et al
    Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
    Blood. 2022;139:3366-3375.
    >> Share

  380. LI Y, Yang X, Sun Y, Li Z, et al
    The Impact of T cell Immunity on Chemotherapy Response in Childhood Acute Lymphoblastic Leukemia.
    Blood. 2022 Jun 8. pii: 485490. doi: 10.1182/blood.2021014495.
    >> Share

  381. ROBIN M, de Wreede LC, Padron E, Bakunina K, et al
    Role of Allogeneic Transplantation In Chronic Myelomonocytic Leukemia: An International Collaborative Analysis.
    Blood. 2022 Jun 6. pii: 485477. doi: 10.1182/blood.2021015173.
    >> Share

  382. SONG H, Liu Y, Tan Y, Zhang Y, et al
    Recurrent non-coding somatic and germline WT1 variants converge to disrupt MYB binding in acute promyelocytic leukemia.
    Blood. 2022 Jun 2. pii: 485457. doi: 10.1182/blood.2021014945.
    >> Share

  383. ROGERS KA, Woyach JA
    A CAPTIVATE-ing new regimen for CLL.
    Blood. 2022;139:3229-3230.
    >> Share

  384. FERNANDEZ-SEVILLA LM, Valencia J, Ortiz-Sanchez P, Fraile-Ramos A, et al
    High BMP4 expression in low/intermediate risk BCP-ALL identifies children with poor outcomes.
    Blood. 2022;139:3303-3313.
    >> Share

  385. TAM CS, Allan JN, Siddiqi T, Kipps TJ, et al
    Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
    Blood. 2022;139:3278-3289.
    >> Share

    May 2022

  386. Genomic landscape of T-LGL leukemia.
    Blood. 2022;139:3100.
    >> Share

  387. SEMENZATO G, Zambello R
    Interrogating molecular genetics to refine LGLL classification.
    Blood. 2022;139:3002-3004.
    >> Share

  388. LAUKKANEN S, Bacquelaine Veloso A, Yan C, Oksa L, et al
    Combination therapies to inhibit LCK tyrosine kinase and mTOR signaling in T-cell Acute Lymphoblastic Leukemia.
    Blood. 2022 May 11. pii: 485213. doi: 10.1182/blood.2021015106.
    >> Share

  389. BIEDERSTADT A, Rezvani K
    How I treat high-risk acute myeloid leukemia using pre-emptive adoptive cellular immunotherapy.
    Blood. 2022 May 5. pii: 485176. doi: 10.1182/blood.2021012411.
    >> Share


  390. Tomizawa D, Miyamura T, Imamura T, et al. A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. Blood. 2020;136(16):1813-1823.
    Blood. 2022;139:2848.
    >> Share

  391. LI L, Kim JH, Lu W, Williams DM, et al
    HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression.
    Blood. 2022;139:2797-2815.
    >> Share

  392. TYAGI A, Ly S, El-Dana F, Yuan B, et al
    Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML.
    Blood. 2022;139:2782-2796.
    >> Share

  393. FREY NV
    Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia.
    Blood. 2022 May 4. pii: 485154. doi: 10.1182/blood.2021014892.
    >> Share

  394. MACIOCIA PM, Wawrzyniecka PA, Maciocia NC, Burley A, et al
    Anti-CCR9 Chimeric Antigen Receptor T cells for T Cell Acute Lymphoblastic Leukemia.
    Blood. 2022 May 4. pii: 485152. doi: 10.1182/blood.2021013648.
    >> Share

    April 2022
  395. CHEN Z, Simon-Molas H, Cretenet G, Valle-Argos B, et al
    Characterization of metabolic alterations of Chronic Lymphocytic Leukemia in the lymph node microenvironment.
    Blood. 2022 Apr 29. pii: 485126. doi: 10.1182/blood.2021013990.
    >> Share

  396. BISHOP MR
    New hope to prevent ALL relapse after transplant.
    Blood. 2022;139:2580-2581.
    >> Share

  397. ZHAO Y, Wang E
    Pure erythroid leukemia evolved from JAK2V617F-positive polycythemia vera: blast phase transformation along erythroid line.
    Blood. 2022;139:2574.
    >> Share

  398. CHIANG MY
    Firing up chromatin to forge T-ALL.
    Blood. 2022;139:2418-2420.
    >> Share

  399. ANTOSZEWSKI M, Fournier N, Ruiz Buendia GA, Lourenco J, et al
    Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL.
    Blood. 2022;139:2483-2498.
    >> Share

  400. DUPLOYEZ N, Largeaud L, Duchmann M, Kim R, et al
    Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study.
    Blood. 2022 Apr 20. pii: 485005. doi: 10.1182/blood.2021015328.
    >> Share

  401. LEWIS AC, Pope VS, Tea MN, Li M, et al
    Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.
    Blood. 2022 Apr 20. pii: 485003. doi: 10.1182/blood.2021013277.
    >> Share

  402. WELCH JS
    TP53 and the star-crossed lovers MDS and AML.
    Blood. 2022;139:2265-2266.
    >> Share

  403. TASHAKORI M, Kadia TM, Loghavi S, Daver NG, et al
    TP53 Copy Number and Protein Expression Inform Mutation Status across Risk Categories in Acute Myeloid Leukemia.
    Blood. 2022 Apr 7. pii: 484631. doi: 10.1182/blood.2021013983.
    >> Share

  404. DANILOV AV
    Immunity in CLL: corrupt at inception?
    Blood. 2022;139:2104-2105.
    >> Share

  405. DEPASQUALE EAK, van Galen P
    Plasticity and immune evasion in childhood ALL.
    Blood. 2022;139:2096-2097.
    >> Share

  406. PURROY N, Tong YE, Lemvigh CK, Cieri N, et al
    Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib.
    Blood. 2022;139:2252-2256.
    >> Share

  407. ROBOZ GJ, Ravandi F, Wei AH, Dombret H, et al
    Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status.
    Blood. 2022;139:2145-2155.
    >> Share

  408. LEAHY AB, Devine KJ, Li Y, Liu H, et al
    Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy.
    Blood. 2022;139:2173-2185.
    >> Share

    March 2022
  409. BELLUSCI L, Grubbs G, Srivastava P, Nemeth MJ, et al
    Neutralization of SARS-CoV-2 Omicron after vaccination of myelodysplastic syndromes and acute myeloid leukemia patients.
    Blood. 2022 Mar 28. pii: 484507. doi: 10.1182/blood.2022016087.
    >> Share

  410. QI Y, Zhao M, Hu Y, Wang Y, et al
    Efficacy and safety of CD19-specific CAR T-cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.
    Blood. 2022 Mar 25. pii: 484499. doi: 10.1182/blood.2021013733.
    >> Share

  411. WANG HY, Heyman BM
    Annexin A1- but CD10+ hairy cell leukemia.
    Blood. 2022;139:1924.
    >> Share

  412. KATER AP, Melenhorst JJ
    Do CARs finally hit the CLL road?
    Blood. 2022;139:1775-1776.
    >> Share

  413. SIDDIQI T, Soumerai JD, Dorritie KA, Stephens DM, et al
    Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
    Blood. 2022;139:1794-1806.
    >> Share

  414. BUCHMANN S, Schrappe M, Baruchel A, Biondi A, et al
    Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium.
    Blood. 2022;139:1785-1793.
    >> Share

  415. BEWERSDORF JP, Patel KK, Goshua G, Shallis RM, et al
    Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia.
    Blood. 2022;139:1766-1770.
    >> Share

  416. PARAS G, Morsink LM, Othus M, Milano F, et al
    Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML.
    Blood. 2022;139:1694-1706.
    >> Share

  417. BEDNARSKI JJ, Zimmerman C, Berrien-Elliott MM, Foltz JA, et al
    Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant.
    Blood. 2022;139:1670-1683.
    >> Share

  418. PARIHAR R
    Memory NK cells to forget relapsed AML.
    Blood. 2022;139:1607-1608.
    >> Share

  419. KLEPIN HD
    Toward consensus on geriatric assessment in AML.
    Blood. 2022;139:1605-1606.
    >> Share

  420. MIN GJ, Cho BS, Park SS, Park S, et al
    Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML.
    Blood. 2022;139:1646-1658.
    >> Share

  421. TRACY SI, Venkatesh H, Hekim C, Heltemes Harris LM, et al
    Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia.
    Blood. 2022 Mar 11. pii: 484383. doi: 10.1182/blood.2021015341.
    >> Share

  422. MATSUOKA M
    Targeting vulnerabilities of adult T-cell leukemia.
    Blood. 2022;139:1435.
    >> Share

  423. NEDUMANNIL R, Juneja S
    Pseudo-Chediak-Higashi inclusions in BCR::ABL1-like B-lymphoblastic leukemia with IGH::EPOR rearrangement.
    Blood. 2022;139:1598.
    >> Share


  424. Silva O, Kurzer J. Nonleukemic T/B mixed phenotype acute leukemia with PHF6 and NOTCH1 mutations. Blood. 2021;138(9):818.
    Blood. 2022;139:1602.
    >> Share

  425. MARTI G
    Premonoclonal B-cell lymphocytosis: the CLL cell of origin.
    Blood. 2022;139:1436-1437.
    >> Share

  426. STIVERS N, Afify Z
    Pediatric B-acute lymphoblastic leukemia presenting with a mass: an underrecognized association.
    Blood. 2022;139:1423.
    >> Share


  427. Awada H, Durmaz A, Gurnari C, et al. Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. Blood. 2021;138(19):1885-1895.
    Blood. 2022;139:1424-1425.
    >> Share

  428. KWOK M, Stankovic T
    The three musketeers: uniting against CLL.
    Blood. 2022;139:1264-1265.
    >> Share

  429. VERRILLS NM
    PP2A activation targets AML stem cells.
    Blood. 2022;139:1267-1269.
    >> Share

    February 2022
  430. MAITI A, Daver NG
    A nonstick marrow may help to fry leukemia.
    Blood. 2022;139:1119-1121.
    >> Share


  431. Lulla PD, Naik S, Vasileiou S, et al. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021;137(19):2585-2597.
    Blood. 2022;139:1257.
    >> Share

  432. BROWN AL
    And the germline beat (AML) goes on.
    Blood. 2022;139:1126-1128.
    >> Share

  433. BERRIEN-ELLIOTT MM, Becker-Hapak M, Cashen AF, Jacobs M, et al
    Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.
    Blood. 2022;139:1177-1183.
    >> Share

  434. YANG F, Long N, Anekpuritanang T, Bottomly D, et al
    Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML.
    Blood. 2022;139:1208-1221.
    >> Share

  435. BLOMBERY P, Lew TE, Dengler MA, Thompson ER, et al
    Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
    Blood. 2022;139:1198-1207.
    >> Share

  436. SIPOL A, Hameister E, Xue B, Hofstetter J, et al
    MondoA drives malignancy in B-ALL through enhanced adaptation to metabolic stress.
    Blood. 2022;139:1184-1197.
    >> Share

  437. KIMURA S, Montefiori L, Iacobucci I, Zhao Y, et al
    Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.
    Blood. 2022 Feb 22. pii: 484108. doi: 10.1182/blood.2022015444.
    >> Share

  438. BANGHAM CRM
    Adult T-cell leukemia: genomic analysis.
    Blood. 2022;139:953-954.
    >> Share

  439. YOU X, Liu F, Binder M, Vedder A, et al
    Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
    Blood. 2022;139:1066-1079.
    >> Share

  440. CAZAUBIEL T, Leleu X, Perrot A, Manier S, et al
    Primary Plasma Cell Leukemia displaying t(11;14) have specific genomic, transcriptional and clinical feature.
    Blood. 2022 Feb 16. pii: 484066. doi: 10.1182/blood.2021014968.
    >> Share

  441. FALINI B, De Carolis L, Tiacci E
    How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.
    Blood. 2022 Feb 10. pii: 483952. doi: 10.1182/blood.2021013502.
    >> Share

  442. WILL B
    Fighting AML with its own weapons.
    Blood. 2022;139:807-809.
    >> Share

  443. MILL CP, Fiskus W, DiNardo CD, Birdwell C, et al
    Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
    Blood. 2022;139:907-921.
    >> Share

  444. HEIKAMP EB, Henrich JA, Perner F, Wong EM, et al
    The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.
    Blood. 2022;139:894-906.
    >> Share

  445. NAIK S, Vasileiou S, Tzannou I, Kuvalekar M, et al
    Donor-Derived Multiple Leukemia Antigen Specific T-cell Therapy to Prevent Relapse Post-Transplant in Patients with ALL.
    Blood. 2022 Feb 8. pii: 483888. doi: 10.1182/blood.2021014648.
    >> Share

  446. LV K, Tong W
    Waking up CML leukemia stem cells for the kill.
    Blood. 2022;139:647-648.
    >> Share

  447. WANG XQ, McGinnis E
    Megakaryocytic emperipolesis as a dyshematopoietic feature in acute myeloid leukemia with inv(16).
    Blood. 2022;139:798.
    >> Share

  448. BHAT SA, Woyach JA
    Boosting BNT162b2 vaccine efficacy in CLL.
    Blood. 2022;139:639-640.
    >> Share

  449. DEAGLIO S, Vaisitti T
    A new taxonomy for splenic marginal zone lymphoma.
    Blood. 2022;139:644-645.
    >> Share

  450. HERISHANU Y, Rahav G, Levi S, Braester A, et al
    Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.
    Blood. 2022;139:678-685.
    >> Share

  451. DAVIDS MS, Rogers KA, Tyekucheva S, Wang Z, et al
    Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
    Blood. 2022;139:686-689.
    >> Share

  452. SASAKI K, Yamauchi T, Semba Y, Nogami J, et al
    Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL.
    Blood. 2022;139:748-760.
    >> Share

  453. GROB T, Al Hinai AS, Sanders MA, Kavelaars F, et al
    MOLECULAR CHARACTERIZATION OF MUTANT TP53 ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME.
    Blood. 2022 Feb 2. pii: 483799. doi: 10.1182/blood.2021014472.
    >> Share

    January 2022
  454. PETERS FS, Kater AP
    Increasing CART cell engine performance in CLL.
    Blood. 2022;139:473-474.
    >> Share

  455. FUNK CR, Wang S, Chen KZ, Waller A, et al
    PI3Kdelta/gamma inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.
    Blood. 2022;139:523-537.
    >> Share

  456. MAN CH, Mercier FE, Liu N, Dong W, et al
    Proton export alkalinizes intracellular pH and reprograms carbon metabolism to drive normal and malignant cell growth.
    Blood. 2022;139:502-522.
    >> Share

  457. ABRAHAM IE, Rauscher GH, Patel AA, Pearse W, et al
    Structural Racism is a Mediator of Disparities in Acute Myeloid Leukemia Outcomes.
    Blood. 2022 Jan 21. pii: 483615. doi: 10.1182/blood.2021012830.
    >> Share

  458. LEE EJ, Bussel JB
    An "ATRA-ctive" new treatment of ITP?
    Blood. 2022;139:307-308.
    >> Share

  459. SOMMERKAMP P, Trumpp A
    Driving differentiation: targeting APA in AML.
    Blood. 2022;139:317-319.
    >> Share

  460. MCCORMACK MP
    T/myeloid MPAL: origin and pathogenesis.
    Blood. 2022;139:313-315.
    >> Share

  461. AARAKAKI H, Karube K
    Small-cell pattern of DUSP22 rearranged ALK-negative anaplastic large-cell lymphoma with leukemic phase.
    Blood. 2022;139:465.
    >> Share

  462. ESTEY E, Hasserjian RP, Dohner H
    Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal.
    Blood. 2022;139:323-332.
    >> Share

  463. WARREN AJ
    Road to RIO-kinase 2 for AML therapy.
    Blood. 2022;139:156-157.
    >> Share

  464. WANG W, Hu Z
    Leukocytosis with left-shifted myeloid maturation in a peripheral blood specimen: a clue to the lymphoid blast phase of CML.
    Blood. 2022;139:305.
    >> Share

  465. BRENDOLAN A, Russo V
    Targeting cholesterol homeostasis in hematopoietic malignancies.
    Blood. 2022;139:165-176.
    >> Share

  466. FUJIHARA M, Sakata R, Yoshida N, Ozasa K, et al
    Incidence of lymphoid neoplasms among atomic bomb survivors by histological subtype, 1950 to 1994.
    Blood. 2022;139:217-227.
    >> Share

  467. CHEON H, Xing JC, Moosic KB, Ung J, et al
    Genomic Landscape of TCR Alpha-Beta and TCR Gamma-Delta T-Large Granular Lymphocyte Leukemia.
    Blood. 2022 Jan 11. pii: 483429. doi: 10.1182/blood.2021013164.
    >> Share

  468. ZHANG YH, Han X
    Acute promyelocytic leukemia with Chediak-Higashi like giant granules.
    Blood. 2022;139:149.
    >> Share

  469. BULLINGER L
    CEBPA mutations in AML: site matters.
    Blood. 2022;139:6-7.
    >> Share

  470. YOUNG PE, Medeiros LJ
    Unexpected myeloid sarcoma of the tonsil in a patient without a history of hematological neoplasm.
    Blood. 2022;139:148.
    >> Share

    December 2021
  471. VOLK A
    Ticket to divide: m6A reader YTHDC1 drives acute myeloid leukemia proliferation.
    Blood. 2021;138:2748-2750.
    >> Share

  472. MORENO C, Mora A
    MRD in CLL: some answers, many questions.
    Blood. 2021;138:2746-2747.
    >> Share

  473. TRAN A, Wong M
    Atypical CML with mutated SRSF2, ASXL1, CSF3R, and MPL.
    Blood. 2021;138:2890.
    >> Share

  474. WANG XV, Hanson CA, Tschumper RC, Lesnick CE, et al
    Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
    Blood. 2021;138:2810-2827.
    >> Share

  475. SHENG Y, Wei J, Yu F, Xu H, et al
    A critical role of nuclear m6A reader YTHDC1 in leukemogenesis by regulating MCM complex-mediated DNA replication.
    Blood. 2021;138:2838-2852.
    >> Share

  476. CAI H, Kondo M, Sandhow L, Xiao P, et al
    Critical Role of Lama4 for Hematopoiesis Regeneration and Acute Myeloid Leukemia Progression.
    Blood. 2021 Dec 27. pii: 483253. doi: 10.1182/blood.2021011510.
    >> Share

  477. POZDNYAKOVA O
    NPM1: not present? Mark!
    Blood. 2021;138:2602-2603.
    >> Share

  478. AL-SAWAF O, Fischer K
    TP53 mutations in CLL: does frequency matter?
    Blood. 2021;138:2600-2601.
    >> Share

  479. UY GL
    Turning AML targets inside out.
    Blood. 2021;138:2598-2599.
    >> Share

  480. TEN HACKEN E, Wu CJ
    Understanding CLL biology through mouse models of human genetics.
    Blood. 2021;138:2621-2631.
    >> Share

  481. RIGOLIN GM, Del Giudice I, Bardi A, Melandri A, et al
    Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.
    Blood. 2021;138:2727-2730.
    >> Share

  482. MARTELLI MP, Rossi R, Venanzi A, Meggendorfer M, et al
    Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML.
    Blood. 2021;138:2696-2701.
    >> Share

  483. AUGSBERGER C, Hanel G, Xu W, Pulko V, et al
    Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
    Blood. 2021;138:2655-2669.
    >> Share

  484. MALCIKOVA J, Pavlova S, Barbara KV, Radova L, et al
    Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.
    Blood. 2021;138:2670-2685.
    >> Share

  485. GABALLA MR, Banerjee PP, Milton DR, Jiang X, et al
    Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia.
    Blood. 2021 Dec 16. pii: 483090. doi: 10.1182/blood.2021013290.
    >> Share

  486. SHOPSOWITZ KE, Slack GW
    B-lymphoblastic lymphoma presenting as a primary breast mass with periductal invasion.
    Blood. 2021;138:2593.
    >> Share

  487. SIVINA M, Kim E, Wierda WG, Ferrajoli A, et al
    Ibrutinib induces durable remissions in treatment-naive patients with CLL and 17p deletion and/or TP53 mutations.
    Blood. 2021;138:2589-2592.
    >> Share

  488. TONC E, Takeuchi Y, Chou C, Xia Y, et al
    Unexpected suppression of tumorigenesis by c-MYC via TFAP4-dependent restriction of stemness in B lymphocytes.
    Blood. 2021;138:2526-2538.
    >> Share

  489. HUBER H, Edenhofer S, von Tresckow J, Robrecht S, et al
    Phase 2 study of obinutuzumab (GA-101), ibrutinib and venetoclax (CLL2-GIVe) in patients with untreated high-risk chronic lymphocytic leukemia.
    Blood. 2021 Dec 15. pii: 483086. doi: 10.1182/blood.2021013208.
    >> Share

  490. ROSENQUIST R
    The more complex, the worse outcome in CLL.
    Blood. 2021;138:2305-2307.
    >> Share

  491. THAKRAL B, Lin P
    Acute myeloid leukemia with erythroid and megakaryocytic differentiation associated with Down syndrome.
    Blood. 2021;138:2446.
    >> Share

  492. HITZLER J, Alonzo T, Gerbing R, Beckman A, et al
    High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial.
    Blood. 2021;138:2337-2346.
    >> Share

  493. KITTAI AS, Miller C, Goldstein D, Huang Y, et al
    The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib.
    Blood. 2021;138:2372-2382.
    >> Share

  494. LI Y, Xie X, Jie Z, Zhu L, et al
    DYRK1a mediates BAFF-induced noncanonical NF-kappaB activation to promote autoimmunity and B-cell leukemogenesis.
    Blood. 2021;138:2360-2371.
    >> Share

  495. WEEKS LD, Marinac CR, Redd RA, Abel GA, et al
    Age-related Diseases of Inflammation in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.
    Blood. 2021 Dec 7. pii: 482919. doi: 10.1182/blood.2021014418.
    >> Share

  496. CHEN C, Yu W, Alikarami F, Qiu Q, et al
    Single-cell multiomics reveals increased plasticity, resistant populations and stem-cell-like blasts in KMT2A-rearranged leukemia.
    Blood. 2021 Dec 5. pii: 482898. doi: 10.1182/blood.2021013442.
    >> Share

  497. BHATIA R
    Fattening up FLT3-ITD for the kill.
    Blood. 2021;138:2158-2159.
    >> Share

    November 2021
  498. SCHWALLER J
    MLL-AF4+ infant leukemia: a microRNA affair.
    Blood. 2021;138:2014-2015.
    >> Share

  499. JACOBS JW, Siddon AJ
    Concurrent COVID-19 and babesiosis in an older, splenectomized patient.
    Blood. 2021;138:2154.
    >> Share

  500. REA D, Mauro MJ, Boquimpani C, Minami Y, et al
    A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
    Blood. 2021;138:2031-2041.
    >> Share

  501. ROSSI M, Meggendorfer M, Zampini M, Tettamanti M, et al
    Clinical relevance of clonal hematopoiesis in persons aged >/=80 years.
    Blood. 2021;138:2093-2105.
    >> Share

  502. MARCAULT C, Zhao LP, Maslah N, Verger E, et al
    Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms.
    Blood. 2021;138:2142-2148.
    >> Share

  503. ISHIO T, Kumar S, Shimono J, Daenthanasanmak A, et al
    Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in Adult T-cell leukemia/lymphoma.
    Blood. 2021 Nov 24. pii: 482776. doi: 10.1182/blood.2021012734.
    >> Share

  504. ZHONG W, Cao X, Pan G, Niu Q, et al
    ORP4L is a prerequisite for the induction of T-cell leukemogenesis associated with human T-cell leukemia virus 1.
    Blood. 2021 Nov 19. pii: 482705. doi: 10.1182/blood.2021013579.
    >> Share

  505. GOSWAMI S, Mani R, Nunes J, Chiang CL, et al
    PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in Acute Myeloid Leukemia.
    Blood. 2021 Nov 17. pii: 482661. doi: 10.1182/blood.2020010344.
    >> Share

  506. ZHAO H, Pomicter AD, Eiring AM, Franzini A, et al
    MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia by Enhancing Common beta Chain Cytokine Receptor Endocytosis.
    Blood. 2021 Nov 15. pii: 477970. doi: 10.1182/blood.2021011802.
    >> Share

  507. THOMAS D
    Machine learning finds new AML subtypes.
    Blood. 2021;138:1790-1792.
    >> Share

  508. DE BOCK CE, Cools J
    BETter insight into PRC2-mutated T-ALL.
    Blood. 2021;138:1787-1788.
    >> Share

  509. CHOI MY
    Improving the outlook for TP53-aberrant CLL.
    Blood. 2021;138:1785-1786.
    >> Share

  510. ANDRIEU GP, Kohn M, Simonin M, Smith CL, et al
    PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL.
    Blood. 2021;138:1855-1869.
    >> Share

  511. CRAMER P, Tausch E, von Tresckow J, Giza A, et al
    Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
    Blood. 2021;138:1805-1816.
    >> Share

  512. MHIBIK M, Gaglione EM, Eik D, Kendall EK, et al
    BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.
    Blood. 2021;138:1843-1854.
    >> Share

  513. LANGERBEINS P, Zhang C, Robrecht S, Cramer P, et al
    The CLL12 trial: Ibrutinib versus placebo in treatment-naive, early stage chronic lymphocytic leukemia.
    Blood. 2021 Nov 10. pii: 477942. doi: 10.1182/blood.2021010845.
    >> Share

  514. HASLE H, Kline RM, Kjeldsen E, Nik-Abdul-Rashid NF, et al
    Germline GATA1s generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype.
    Blood. 2021 Nov 10. pii: 477943. doi: 10.1182/blood.2021011463.
    >> Share

  515. FENG Y, Feng W
    Numerous ring sideroblasts in chronic neutrophilic leukemia.
    Blood. 2021;138:1783.
    >> Share

  516. HERISHANU Y, Perry C
    COVID-19 in patients with CLL: how can we change the odds?
    Blood. 2021;138:1652-1653.
    >> Share

  517. ROEKER LE, Eyre TA, Thompson MC, Lamanna N, et al
    COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
    Blood. 2021;138:1768-1773.
    >> Share

  518. HEUSER M, Freeman SD, Ossenkoppele GJ, Buccisano F, et al
    2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document.
    Blood. 2021 Nov 1. pii: 477736. doi: 10.1182/blood.2021013626.
    >> Share

    October 2021
  519. CARTER BZ, Tao W, Mak PY, Ostermann LB, et al
    Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML.
    Blood. 2021;138:1637-1641.
    >> Share

  520. KOGURE Y, Kameda T, Koya J, Yoshimitsu M, et al
    Whole-genome landscape of adult T-cell leukemia/lymphoma.
    Blood. 2021 Oct 25. pii: S0006-4971(21)01784-5. doi: 10.1182/blood.2021013568.
    >> Share

  521. SCHNOEDER TM, Schwarzer A, Jayavelu AK, Hsu CJ, et al
    PLCG1 is required for AML1-ETO leukemia stem cell self-renewal.
    Blood. 2021 Oct 25. pii: S0006-4971(21)01783-3. doi: 10.1182/blood.2021012778.
    >> Share

  522. YASUDA T, Sanada M, Kawazu M, Kojima S, et al
    Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations.
    Blood. 2021 Oct 25. pii: S0006-4971(21)01785-7. doi: 10.1182/blood.2021011921.
    >> Share

  523. ZHAO Y, Wang E
    Plasmablastic myeloma/leukemia variant of monomorphic posttransplant lymphoproliferative disorder.
    Blood. 2021;138:1510.
    >> Share

  524. HAUER J, Fischer U, Borkhardt A
    Toward prevention of childhood ALL by early-life immune training.
    Blood. 2021;138:1412-1428.
    >> Share

  525. JEBARAJ BMC, Muller A, Dheenadayalan RP, Endres S, et al
    Evaluation of vecabrutinib as a model for non-covalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.
    Blood. 2021 Oct 18. pii: 477372. doi: 10.1182/blood.2021011516.
    >> Share

  526. KOLIJN PMM, Saberi Hosnijeh F, Spath F, Hengeveld PJ, et al
    HIGH-RISK SUBTYPES OF CHRONIC LYMPHOCYTIC LEUKEMIA ARE DETECTABLE AS EARLY AS 16 YEARS PRIOR TO DIAGNOSIS.
    Blood. 2021 Oct 18. pii: 477373. doi: 10.1182/blood.2021012890.
    >> Share

  527. TRINH BQ, Ummarino S, Zhang Y, Ebralidze AK, et al
    Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML.
    Blood. 2021;138:1331-1344.
    >> Share

  528. FISHMAN H, Madiwale S, Geron I, Bari V, et al
    ETV6-NCOA2 fusion induces T/Myeloid mixed-phenotype leukemia by transformation of non-thymic hematopoietic progenitors.
    Blood. 2021 Oct 8. pii: 477216. doi: 10.1182/blood.2020010405.
    >> Share

  529. PROSSER AL, Li W
    Salmon-colored granules in the leukemic blasts of B-lymphoblastic leukemia with iAMP21.
    Blood. 2021;138:1282.
    >> Share

    September 2021
  530. SIERRA J, Nomdedeu JF
    CEBPA bZip mutations: just a single shot.
    Blood. 2021;138:1091-1092.
    >> Share

  531. XU D, Naresh KN
    Leukemic presentation of a highly aggressive ALK-negative anaplastic large cell lymphoma.
    Blood. 2021;138:1198.
    >> Share

  532. STEPHENS DM, Byrd JC
    Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.
    Blood. 2021;138:1099-1109.
    >> Share

  533. TARLOCK K, Lamble AJ, Wang YC, Gerbing RB, et al
    CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
    Blood. 2021;138:1137-1147.
    >> Share

  534. ALEJO-VALLE O, Weigert K, Bhayadia R, Ng M, et al
    The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis.
    Blood. 2021 Sep 27. pii: 477055. doi: 10.1182/blood.2021012231.
    >> Share

  535. PALLASCH CP
    Cell cycle control in Richter transformation.
    Blood. 2021;138:1005-1007.
    >> Share

  536. HAN C, Ntziachristos P
    T-ALL and the talented Mr IL7Ralpha.
    Blood. 2021;138:1003-1004.
    >> Share

  537. YU X, Munoz-Sagredo L, Streule K, Muschong P, et al
    CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues.
    Blood. 2021;138:1067-1080.
    >> Share

  538. CHAKRABORTY S, Martines C, Porro F, Fortunati I, et al
    B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation.
    Blood. 2021;138:1053-1066.
    >> Share

  539. DEANGELO DJ, Jonas BA, Liesveld JL, Bixby DL, et al
    Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia.
    Blood. 2021 Sep 20. pii: 476977. doi: 10.1182/blood.2021010721.
    >> Share

  540. BERMAN E
    How I Treat Chronic Phase Chronic Myelogenous Leukemia.
    Blood. 2021 Sep 16. pii: 476939. doi: 10.1182/blood.2021011722.
    >> Share

  541. PAIETTA E, Roberts KG, Wang V, Gu Z, et al
    Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.
    Blood. 2021;138:948-958.
    >> Share

  542. AMAYA M, Inguva A, Pei S, Jones CL, et al
    The STAT3-MYC Axis Promotes Survival of Leukemia Stem Cells by Regulating SLC1A5 and Oxidative Phosphorylation.
    Blood. 2021 Sep 15. pii: 476917. doi: 10.1182/blood.2021013201.
    >> Share

  543. SAMARAWEERA SE, Wang PP, Li KL, Casolari DA, et al
    Childhood Acute Myeloid Leukemia shows a high level of germline predisposition.
    Blood. 2021 Sep 14. pii: 476894. doi: 10.1182/blood.2021012666.
    >> Share

  544. ROSSOFF J, Baggott C, Prabhu S, Pacenta HL, et al
    Out of Specification Tisagenlecleucel Does Not Compromise Safety or Efficacy in Pediatric Acute Lymphoblastic Leukemia.
    Blood. 2021 Sep 9. pii: 476839. doi: 10.1182/blood.2021012392.
    >> Share

  545. MA S, Seymour JF, Brander DM, Kipps TJ, et al
    Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.
    Blood. 2021;138:836-846.
    >> Share

  546. DAVIS AG, Johnson DT, Zheng D, Wang R, et al
    Alternative polyadenylation dysregulation contributes to the differentiation block of acute myeloid leukemia.
    Blood. 2021 Sep 5. pii: 476791. doi: 10.1182/blood.2020005693.
    >> Share

  547. MEIJERINK JPP
    BCL11B, the Cerberus of human leukemia.
    Blood. 2021;138:741-743.
    >> Share

  548. SILVA O, Kurzer J
    Nonleukemic T/B mixed phenotype acute leukemia with PHF6 and NOTCH1 mutations.
    Blood. 2021;138:818.
    >> Share

  549. IMGRUET MK, Lutze J, An N, Hu B, et al
    Loss of a 7q gene, CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms.
    Blood. 2021;138:790-805.
    >> Share

    August 2021
  550. HERLING M, Wahnschaffe L
    Altered epigenetics at the center of NK-LGL leukemia.
    Blood. 2021;138:589-591.
    >> Share

  551. WHEAT JC, Steidl U
    Gene expression at a single-molecule level: implications for myelodysplastic syndromes and acute myeloid leukemia.
    Blood. 2021;138:625-636.
    >> Share

  552. JANN JC, Tothova Z
    Cohesin mutations in myeloid malignancies.
    Blood. 2021;138:649-661.
    >> Share

  553. QING Y, Su R, Chen J
    RNA modifications in hematopoietic malignancies: a new research frontier.
    Blood. 2021;138:637-648.
    >> Share

  554. MESSLING JE, Agger K, Andersen KL, Kromer K, et al
    Targeting RIOK2 ATPase activity leads to decreased protein synthesis and cell death in acute myeloid leukemia.
    Blood. 2021 Aug 25. pii: 476529. doi: 10.1182/blood.2021012629.
    >> Share

  555. ASTOLFI A, Masetti R, Indio V, Bertuccio SN, et al
    Torque Teno Mini Virus as a cause of childhood acute promyelocytic leukemia lacking PML/RARA fusion.
    Blood. 2021 Aug 25. pii: 476664. doi: 10.1182/blood.2021011677.
    >> Share

  556. ZANETTI C, Kumar R, Ender J, Godavarthy PS, et al
    The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13.
    Blood. 2021 Aug 23. pii: 476652. doi: 10.1182/blood.2021011557.
    >> Share

  557. DERECKA M
    AML onco-niche: villain or ally?
    Blood. 2021;138:504-506.
    >> Share

  558. BURGER JA
    CLL cells are moved by the MARCKS brothers.
    Blood. 2021;138:503-504.
    >> Share

  559. SCHILLER G
    A slow-go prognosis for older patients with newly diagnosed AML.
    Blood. 2021;138:501-502.
    >> Share


  560. Genetic decision model for fit older AML patients.
    Blood. 2021;138:585.
    >> Share

  561. ITZYKSON R, Fournier E, Berthon C, Rollig C, et al
    Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.
    Blood. 2021;138:507-519.
    >> Share

  562. WUDHIKARN K, Flynn JR, Riviere I, Gonen M, et al
    Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy.
    Blood. 2021;138:531-543.
    >> Share

  563. BECKMANN L, Berg V, Dickhut C, Sun C, et al
    MARCKS affects cell motility and response to BTK inhibitors in CLL.
    Blood. 2021;138:544-556.
    >> Share

  564. CORTES J, Apperley JF, Lomaia E, Moiraghi B, et al
    Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial.
    Blood. 2021 Aug 18. pii: 476603. doi: 10.1182/blood.2021012082.
    >> Share

  565. GUO D, Zhao Y, Wang N, You N, et al
    GADD45g acts as a novel tumor suppressor, and its activation suggests new combination regimens for the treatment of AML.
    Blood. 2021;138:464-479.
    >> Share

  566. ALVES DA SILVA PH, Xing S, Kotini AG, Papapetrou EP, et al
    MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia.
    Blood. 2021 Aug 6. pii: 476528. doi: 10.1182/blood.2021011619.
    >> Share

  567. YANG S, Zhu XN, Zhang HL, Yang Q, et al
    ANP32B-mediated repression of p53 contributes to maintenance of normal and CML stem cells.
    Blood. 2021 Aug 6. pii: 476526. doi: 10.1182/blood.2020010400.
    >> Share

  568. SORROR ML, Storer BE, Fathi AT, Brunner A, et al
    Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.
    Blood. 2021;138:387-400.
    >> Share

    July 2021
  569. HALSEY C, Escherich G
    A "Goldilocks" approach to CNS leukemia is needed.
    Blood. 2021;138:288-289.
    >> Share

  570. SAUER T, Parikh K, Sharma S, Omer B, et al
    CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity.
    Blood. 2021;138:318-330.
    >> Share

  571. TAUBE F, Georgi JA, Kramer M, Stasik S, et al
    CEBPA Mutations in 4708 Patients with Acute Myeloid Leukemia - Differential Impact of bZIP and TAD Mutations on Outcome.
    Blood. 2021 Jul 28. pii: 476465. doi: 10.1182/blood.2020009680.
    >> Share

  572. KOLLMANN S, Grausenburger R, Klampfl T, Prchal-Murphy M, et al
    A STAT5B-CD9 axis determines self-renewal in hematopoietic and leukemic stem cells.
    Blood. 2021 Jul 28. pii: 476469. doi: 10.1182/blood.2021010980.
    >> Share

  573. PUZZOLO MC, Radice G, Peragine N, de Propris MS, et al
    Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab.
    Blood. 2021 Jul 23. pii: 476452. doi: 10.1182/blood.2021011822.
    >> Share

  574. GOOPTU M, Romee R, St Martin A, Arora M, et al
    HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis.
    Blood. 2021;138:273-282.
    >> Share

  575. LEE JB, Khan DH, Hurren R, Xu M, et al
    Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production.
    Blood. 2021;138:234-245.
    >> Share

  576. MORANDE PE, Yan XJ, Sepulveda J, Seija N, et al
    AID overexpression leads to aggressive murine CLL and nonimmunoglobulin mutations that mirror human neoplasms.
    Blood. 2021;138:246-258.
    >> Share

  577. JETANI H, Navarro-Bailon A, Maucher M, Frenz S, et al
    Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (AML).
    Blood. 2021 Jul 21. pii: 476427. doi: 10.1182/blood.2020009192.
    >> Share

  578. BUTLER M, van Ingen Schenau DS, Yu J, Jenni S, et al
    BTK inhibition sensitizes Acute Lymphoblastic Leukemia to asparaginase by suppressing the Amino Acid Response pathway.
    Blood. 2021 Jul 19. pii: 476421. doi: 10.1182/blood.2021011787.
    >> Share

  579. KUTSCH N
    CLL-IPI: valid in the era of oral inhibitors?
    Blood. 2021;138:106-107.
    >> Share

  580. PARIKH SA, Rabe KG, Kay NE, Call TG, et al
    The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL.
    Blood. 2021;138:149-159.
    >> Share

  581. MULET-LAZARO R, van Herk S, Erpelinck C, Bindels E, et al
    Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML.
    Blood. 2021;138:160-177.
    >> Share

  582. ZHENG W, Wei J, Zebley CC, Jones LL, et al
    Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-T-cell responses against ALL.
    Blood. 2021;138:122-135.
    >> Share

  583. KRANC KR
    The essential reading list for AML: the m6A transcripts.
    Blood. 2021;138:6-7.
    >> Share

  584. LINLEY AJ, Slupsky JR
    Poor prognosis is ZAP70'ed into focus in CLL.
    Blood. 2021;137:3586-3587.
    >> Share

    June 2021
  585. MEIER-ABT F, Lu J, Cannizzaro E, Pohly MF, et al
    The Protein Landscape of Chronic Lymphocytic Leukemia (CLL).
    Blood. 2021 Jun 29. pii: 476272. doi: 10.1182/blood.2020009741.
    >> Share

  586. TABE Y, Konopleva M
    Break the lifeline of AML cells.
    Blood. 2021;137:3465-3467.
    >> Share

  587. MORENO C
    Autoimmune cytopenia and CLL ride together.
    Blood. 2021;137:3464-3465.
    >> Share

  588. VITALE C, Salvetti C, Griggio V, Porrazzo M, et al
    Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
    Blood. 2021;137:3507-3517.
    >> Share

  589. MULLER MR
    A new option for Richter syndrome.
    Blood. 2021;137:3318-3319.
    >> Share

  590. SMOLEJ L
    On the road to optimized BTK inhibition in CLL.
    Blood. 2021;137:3313-3314.
    >> Share

  591. LOKE J, Cockerill PN
    Unravelling the apoptotic machinery in CMML.
    Blood. 2021;137:3321-3322.
    >> Share

  592. IANNELLO A, Vitale N, Coma S, Arruga F, et al
    Synergistic efficacy of the dual PI3K-delta/gamma inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models.
    Blood. 2021;137:3378-3389.
    >> Share

  593. SEVIN M, Debeurme F, Laplane L, Badel S, et al
    Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML.
    Blood. 2021;137:3390-3402.
    >> Share

  594. VAISITTI T, Arruga F, Vitale N, Lee TT, et al
    ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models.
    Blood. 2021;137:3365-3377.
    >> Share

  595. KATERNDAHL CDS, Rogers ORS, Day RB, Cai MA, et al
    Tumor suppressor function of Gata2 in Acute Promyelocytic Leukemia.
    Blood. 2021 Jun 14. pii: 476182. doi: 10.1182/blood.2021011758.
    >> Share

  596. RUBNITZ JE, Kaspers GJL
    How I treat pediatric acute myeloid leukemia.
    Blood. 2021 Jun 11. pii: 476140. doi: 10.1182/blood.2021011694.
    >> Share

  597. LV K, Ren JG, Han X, Gui J, et al
    Depalmitoylation Rewires FLT3-ITD Signaling and Exacerbates Leukemia Progression.
    Blood. 2021 Jun 10. pii: 476131. doi: 10.1182/blood.2021011582.
    >> Share

  598. MALOUF C, Antunes ETB, O'Dwyer M, Jakobczyk H, et al
    MiR-130b and miR-128a are essential lineage-specific co-drivers of t(4;11) MLL-AF4 acute leukemia.
    Blood. 2021 Jun 10. pii: 476129. doi: 10.1182/blood.2020006610.
    >> Share

  599. CHANG Y, Min J, Jarusiewicz J, Actis M, et al
    Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.
    Blood. 2021 Jun 10. pii: 476126. doi: 10.1182/blood.2020006846.
    >> Share

  600. EICHHORST B
    Vaccination against COVID-19: a challenge in CLL.
    Blood. 2021;137:3153-3154.
    >> Share

  601. WILLIAMS KM
    Checkpoint-blocked T cells checkmate AML.
    Blood. 2021;137:3155-3156.
    >> Share

  602. HERLING M, Braun T
    Tracing the roots of CLPD-NK by TET2 and STAT3.
    Blood. 2021;137:3156-3158.
    >> Share

  603. YUAN Y, Boyle S
    All that glitters is not gold: pseudoplatelets associated with tumour lysis in high-blast-count AML.
    Blood. 2021;137:3310.
    >> Share

  604. PENTER L, Zhang Y, Savell A, Huang T, et al
    Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
    Blood. 2021;137:3212-3217.
    >> Share

  605. FOSTER MC, Savoldo B, Lau W, Rubinos C, et al
    Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity.
    Blood. 2021;137:3306-3309.
    >> Share

  606. BOLDRIN E, Gaffo E, Niedermayer A, Boer JM, et al
    MicroRNA-497/195 is tumor-suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia.
    Blood. 2021 Jun 7. pii: 476100. doi: 10.1182/blood.2020007591.
    >> Share

  607. JONES RJ, DeBaun MR
    Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both or neither.
    Blood. 2021 Jun 3. pii: 476065. doi: 10.1182/blood.2021011488.
    >> Share

  608. TANAKA T, Morita K, Wang F, Loghavi S, et al
    Clonal Dynamics and clinical implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML).
    Blood. 2021 Jun 3. pii: 476064. doi: 10.1182/blood.2020010483.
    >> Share

  609. KORTYLEWSKI M
    Revisiting TLR9 as a target for CLL therapy.
    Blood. 2021;137:3006-3008.
    >> Share

  610. WERMKE M, Kraus S, Ehninger A, Bargou RC, et al
    Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML.
    Blood. 2021;137:3145-3148.
    >> Share

  611. SOMASUNDARAM R, Jensen CT, Tingvall-Gustafsson J, Ahsberg J, et al
    EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene.
    Blood. 2021;137:3037-3049.
    >> Share

  612. DUAULT C, Kumar A, Taghi Khani A, Lee SJ, et al
    Activated Natural Killer Cells Predict Poor Clinical Prognosis in High-risk B- and T- cell Acute Lymphoblastic Leukemia.
    Blood. 2021 Jun 2. pii: 476053. doi: 10.1182/blood.2020009871.
    >> Share

  613. AWADA H, Durmaz A, Gurnari C, Kishtagari A, et al
    Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and Secondary Acute Myeloid Leukemia.
    Blood. 2021 Jun 1. pii: 476049. doi: 10.1182/blood.2020010603.
    >> Share

  614. STEVENSON FK, Forconi F, Kipps TJ
    Exploring the Pathways to Chronic Lymphocytic Leukemia.
    Blood. 2021 Jun 1. pii: 476048. doi: 10.1182/blood.2020010029.
    >> Share

  615. THOMS JAI, Truong P, Subramanian S, Knezevic K, et al
    Disruption of a GATA2, TAL1, ERG regulatory circuit promotes erythroid transition in healthy and leukemic stem cells.
    Blood. 2021 Jun 1. pii: 476046. doi: 10.1182/blood.2020009707.
    >> Share

    May 2021
  616. GHIA P, Stamatopoulos K
    In CLL, epigenetics also points to the BCR.
    Blood. 2021;137:2863-2865.
    >> Share

  617. MASS J, Park DC
    Posttransplant T lymphoblastic lymphoma mimicking Burkitt lymphoma.
    Blood. 2021;137:3002.
    >> Share

  618. COORENS THH, Collord G, Lu W, Mitchell E, et al
    Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment.
    Blood. 2021;137:2992-2997.
    >> Share

  619. WANG D, Wang J, Hu G, Wang W, et al
    A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
    Blood. 2021;137:2890-2901.
    >> Share

  620. FOWLER N
    Kinase inhibitors in CLL: drawing the roadmap.
    Blood. 2021;137:2717-2719.
    >> Share

  621. GANSER A
    What can Heraclitus tell us about AML?
    Blood. 2021;137:2719-2720.
    >> Share

  622. LIU H
    Basophilic myeloblasts: a clue for CML blast phase.
    Blood. 2021;137:2852.
    >> Share

  623. MUSANI R, Chang H
    Coexistence of BCR-ABL1 and RUNX1-RUNX1T1 in a de novo AML.
    Blood. 2021;137:2853.
    >> Share

  624. DUCHMANN M, Micol JB, Duployez N, Raffoux E, et al
    Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.
    Blood. 2021;137:2827-2837.
    >> Share

  625. THIJSSEN R, Diepstraten ST, Moujalled D, Chew E, et al
    Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
    Blood. 2021;137:2721-2735.
    >> Share

  626. MATO AR, Ghosh N, Schuster SJ, Lamanna N, et al
    Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kdelta inhibitor therapy.
    Blood. 2021;137:2817-2826.
    >> Share

  627. BORELLA G, Da Ros A, Borile G, Porcu E, et al
    Targeting mesenchymal stromal cells plasticity to reroute acute myeloid leukemia course.
    Blood. 2021 May 19. pii: 475978. doi: 10.1182/blood.2020009845.
    >> Share

  628. VAN DER KOUWE E, Heller G, Czibere A, Pulikkan JA, et al
    Core binding factor leukemia hijacks T-cell prone PU.1 antisense promoter.
    Blood. 2021 May 19. pii: 475975. doi: 10.1182/blood.2020008971.
    >> Share

  629. BISHOP DC, Clancy LE, Simms R, Burgess J, et al
    Development of CAR T-cell lymphoma in two of ten patients effectively treated with piggyBac modified CD19 CAR T-cells.
    Blood. 2021 May 19. pii: 475980. doi: 10.1182/blood.2021010813.
    >> Share

  630. ESCRIBANO SERRAT S, Calo Perez A
    Pure erythroid leukemia.
    Blood. 2021;137:2709.
    >> Share

  631. TAKEDA MR, Gurbuxani S
    bcr3 PML-RARA: short fusion, small blasts!
    Blood. 2021;137:2708.
    >> Share

  632. SURAPALLY S, Tenen DG, Pulikkan JA
    Emerging therapies for inv(16) AML.
    Blood. 2021;137:2579-2584.
    >> Share

  633. KIRCHHOFF H, Karsli U, Schoenherr C, Battmer K, et al
    Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL.
    Blood. 2021;137:2657-2661.
    >> Share

  634. MICKLETHWAITE KP, Gowrishankar K, Gloss BS, Li Z, et al
    Investigation of product derived lymphoma following infusion of piggyBac modified CD19 chimeric antigen receptor T-cells.
    Blood. 2021 May 11. pii: 475942. doi: 10.1182/blood.2021010858.
    >> Share

  635. SILVA AP, Almeida ARM, Cachucho A, Neto JL, et al
    Overexpression of wild type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma.
    Blood. 2021 May 10. pii: 475938. doi: 10.1182/blood.2019000553.
    >> Share

  636. WIMMER J, Hurstel R
    Systemic mastocytosis with an associated t(8;21)(q22;q22) acute myeloid leukemia.
    Blood. 2021;137:2564.
    >> Share

  637. PADI SKR, Kraft AS
    "Root"ing for successful T-ALL treatment.
    Blood. 2021;137:2422-2423.
    >> Share

  638. GEOFFROY MC, Esnault C, de The H
    Retinoids in hematology: a timely revival?
    Blood. 2021;137:2429-2437.
    >> Share

  639. ANAND P, Guillaumet-Adkins A, Dimitrova V, Yun H, et al
    Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL.
    Blood. 2021;137:2463-2480.
    >> Share

    April 2021
  640. ANDRIEU GP, Asnafi V
    Integrated omics approaches to predict T-LBL relapse risk.
    Blood. 2021;137:2280-2282.
    >> Share

  641. TERRE C, Raggueneau V
    Double insertion in normal karyotype CML.
    Blood. 2021;137:2418.
    >> Share

  642. SORROR ML, Storer BE, Fathi AT, Brunner AM, et al
    Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia.
    Blood. 2021 Apr 28. pii: 475848. doi: 10.1182/blood.2020008812.
    >> Share

  643. CHATZIDIMITRIOU C, Vassilakopoulos TP
    Rapidly deteriorating B-CLL at presentation: clonally related Burkitt leukemia as an atypical Richter transformation?
    Blood. 2021;137:2272.
    >> Share

  644. RINGSHAUSEN I
    IL-9 in CLL: sensing home and settling down!
    Blood. 2021;137:2130-2131.
    >> Share

  645. SOARES F, Chen B, Lee JB, Ahmed M, et al
    CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy.
    Blood. 2021;137:2171-2181.
    >> Share

  646. DA SILVA-DIZ V, Cao B, Lancho O, Chiles E, et al
    A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia.
    Blood. 2021 Apr 19. pii: 475782. doi: 10.1182/blood.2020008955.
    >> Share

  647. MITTELMAN SD, Kim J, Raca G, Li G, et al
    Increased prevalence of CRLF2 rearrangements in obesity-associated acute lymphoblastic leukemia.
    Blood. 2021 Apr 19. pii: 475790. doi: 10.1182/blood.2021011106.
    >> Share

  648. LEW TE, Tam CS, Seymour JF
    How I treat chronic lymphocytic leukemia after venetoclax.
    Blood. 2021 Apr 19. pii: 475780. doi: 10.1182/blood.2020008502.
    >> Share

  649. DI GIACOMO D, La Starza R, Gorello P, Pellanera F, et al
    14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T and myeloid immature acute leukemia.
    Blood. 2021 Apr 19. pii: 475778. doi: 10.1182/blood.2020010510.
    >> Share

  650. HERISHANU Y, Avivi I, Aharon A, Shefer G, et al
    Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia.
    Blood. 2021 Apr 16. pii: 475742. doi: 10.1182/blood.2021011568.
    >> Share

  651. AMES E, Silva O
    Polytypic T-cell prolymphocytic leukemia.
    Blood. 2021;137:2125.
    >> Share

  652. SANDBERG Y, Weerkamp F
    Charcot-Leyden crystals in chronic eosinophilic leukemia.
    Blood. 2021;137:1985.
    >> Share

  653. SEFTEL MD
    Has MRD graduated from its adolescence in ALL?
    Blood. 2021;137:1846-1847.
    >> Share

  654. KENNEDY GA, Tey SK, Buizen L, Varelias A, et al
    A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis.
    Blood. 2021;137:1970-1979.
    >> Share

  655. GEMENETZI K, Psomopoulos F, Carriles AA, Gounari M, et al
    Higher-order immunoglobulin repertoire restrictions in CLL: the illustrative case of stereotyped subsets 2 and 169.
    Blood. 2021;137:1895-1904.
    >> Share

  656. SHAH BD, Bishop MR, Oluwole OO, Logan AC, et al
    KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
    Blood. 2021 Apr 7. pii: 475697. doi: 10.1182/blood.2020009098.
    >> Share

  657. WEI AH, Daver N
    Taking aim at IDH in fitter patients with AML.
    Blood. 2021;137:1706-1707.
    >> Share

  658. SCHWAB C, Roberts K, Boer JM, Gohring G, et al
    SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome.
    Blood. 2021;137:1835-1838.
    >> Share

  659. STEIN EM, DiNardo CD, Fathi AT, Mims AS, et al
    Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
    Blood. 2021;137:1792-1803.
    >> Share

    March 2021
  660. IACOBUCCI I, Qu C, Varotto E, Janke LJ, et al
    Modeling and targeting of erythroleukemia by hematopoietic genome editing.
    Blood. 2021;137:1628-1640.
    >> Share

  661. SIMONIN M, Lhermitte L, Dourthe ME, Lengline E, et al
    IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL.
    Blood. 2021;137:1690-1694.
    >> Share

  662. HOSOKAWA K, Mizumaki H, Yoroidaka T, Maruyama H, et al
    HLA class I allele-lacking leukocytes predict rare clonal evolution to MDS/AML in patients with acquired aplastic anemia.
    Blood. 2021 Mar 22. pii: 475586. doi: 10.1182/blood.2020010586.
    >> Share

  663. KOGAN SC
    PML-RARalpha: changing myeloid networks.
    Blood. 2021;137:1439-1440.
    >> Share

  664. ERNST MPT, Kavelaars FG, Lowenberg B, Valk PJM, et al
    RUNX1 germline variants in RUNX1-mutant AML: how frequent?
    Blood. 2021;137:1428-1431.
    >> Share

  665. AGATHANGELIDIS A, Chatzidimitriou A, Gemenetzi K, Giudicelli V, et al
    Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.
    Blood. 2021;137:1365-1376.
    >> Share

  666. NAZHA A
    Should I rock the boat? When to stop TKIs in CML.
    Blood. 2021;137:1136-1137.
    >> Share

    February 2021
  667. DE MOERLOOSE B
    CAR-T treatment of pediatric AML: a long and winding road.
    Blood. 2021;137:1004-1006.
    >> Share

  668. MICHALLET AS, Letestu R, Le Garff-Tavernier M, Aanei C, et al
    A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
    Blood. 2021;137:1019-1023.
    >> Share

  669. WILLIER S, Rothamel P, Hastreiter M, Wilhelm J, et al
    CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy.
    Blood. 2021;137:1037-1049.
    >> Share

  670. HOFF FW, van Dijk AD, Qiu Y, Ruvolo PP, et al
    Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report.
    Blood. 2021;137:1050-1060.
    >> Share

  671. QAYED M, Ahn KW, Kitko CL, Johnson MH, et al
    A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation.
    Blood. 2021;137:983-993.
    >> Share

  672. SERA Y, Nakata Y, Ueda T, Yamasaki N, et al
    UTX maintains the functional integrity of the murine hematopoietic system by globally regulating aging-associated genes.
    Blood. 2021;137:908-922.
    >> Share

  673. LEONARD JT, Kosaka Y, Malla P, LaTocha D, et al
    Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.
    Blood. 2021;137:939-944.
    >> Share

  674. GILL S
    DARTs point the way forward in AML.
    Blood. 2021;137:720-721.
    >> Share

  675. NG AP
    Unraveling a T-ALL Tapestri.
    Blood. 2021;137:726-727.
    >> Share

  676. HERGOTT CB, Pozdnyakova O
    Beware the "other AML": hepatic angiomyolipoma with extensive extramedullary hematopoiesis.
    Blood. 2021;137:860.
    >> Share

  677. GRANT S
    Targeting cereblon in AML.
    Blood. 2021;137:584-586.
    >> Share

  678. BROWN JR
    AKT: a key to RT?
    Blood. 2021;137:582-584.
    >> Share

  679. KOHLHAAS V, Blakemore SJ, Al-Maarri M, Nickel N, et al
    Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.
    Blood. 2021;137:646-660.
    >> Share

  680. FALINI B, Brunetti L, Martelli MP
    How I diagnose and treat NPM1-mutated AML.
    Blood. 2021;137:589-599.
    >> Share

    January 2021
  681. SHOUVAL R, Soiffer RJ
    Primum non nocere: allo-HSCT for AML in CR1.
    Blood. 2021;137:438-439.
    >> Share

  682. COHEN AUBART F, Roos-Weil D, Armand M, Marceau-Renaut A, et al
    High frequency of clonal hematopoiesis in Erdheim-Chester disease.
    Blood. 2021;137:485-492.
    >> Share

  683. ZHAO Y, Aldoss I, Qu C, Crawford JC, et al
    Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.
    Blood. 2021;137:471-484.
    >> Share

  684. RIO-MACHIN A, Fitzgibbon J
    Germline ETV6 variants: not ALL created equally.
    Blood. 2021;137:288-289.
    >> Share

  685. GAUTHIER J, Bezerra ED, Hirayama AV, Fiorenza S, et al
    Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
    Blood. 2021;137:323-335.
    >> Share

  686. MERTENS D, Kronke J
    Triggering T-cell activity in CLL.
    Blood. 2021;137:150-151.
    >> Share

  687. MASS J, Alobeid B
    Composite mantle cell lymphoma and small lymphocytic lymphoma in a lymph node.
    Blood. 2021;137:282.
    >> Share

  688. AL MOOSAWI M, Vercauteren S
    Cerebrospinal fluid with unusual natural killer cell population.
    Blood. 2021;137:281.
    >> Share

  689. IOANNOU N, Hagner PR, Stokes M, Gandhi AK, et al
    Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
    Blood. 2021;137:216-231.
    >> Share

  690. CORRE J
    Undetectable MRD can change the deal.
    Blood. 2021;137:5-6.
    >> Share

  691. KEESHAN K
    Superenhancing AML with Trib1.
    Blood. 2021;137:8-9.
    >> Share

    December 2020
  692. KAPP-SCHWOERER S, Weber D, Corbacioglu A, Gaidzik VI, et al
    Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.
    Blood. 2020;136:3041-3050.
    >> Share

  693. MIAO H, Kim E, Chen D, Purohit T, et al
    Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations.
    Blood. 2020;136:2958-2963.
    >> Share

  694. LIU Y, Panetta JC, Yang W, Karol SE, et al
    Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatment.
    Blood. 2020;136:2955-2958.
    >> Share

  695. HASELAGER MV, Kielbassa K, Ter Burg J, Bax DJC, et al
    Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
    Blood. 2020;136:2918-2926.
    >> Share

  696. OBERBECK S, Schrader A, Warner K, Jungherz D, et al
    Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.
    Blood. 2020;136:2786-2802.
    >> Share

  697. SALLMAN DA, McLemore AF, Aldrich AL, Komrokji RS, et al
    TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
    Blood. 2020;136:2812-2823.
    >> Share

  698. STAUBER J, Greally J, Steidl U
    Preleukemic and Leukemic Evolution at the Stem Cell Level.
    Blood. 2020 Dec 4. pii: 474417. doi: 10.1182/blood.2019004397.
    >> Share

    November 2020
  699. CORTES J
    How to manage CML patients with comorbidities.
    Blood. 2020;136:2507-2512.
    >> Share

  700. DZAMA MM, Steiner M, Rausch J, Sasca D, et al
    Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
    Blood. 2020;136:2442-2456.
    >> Share

  701. WATANABE A, Miyake K, Nordlund J, Syvanen AC, et al
    Association of aberrant ASNS imprinting with asparaginase sensitivity and chromosomal abnormality in childhood BCP-ALL.
    Blood. 2020;136:2319-2333.
    >> Share

  702. HANEKAMP D, Ngai LL, Janssen JJ, van de Loosdrecht AA, et al
    Early assessment of clofarabine effectiveness applying measurable residual disease, including AML stem cells.
    Blood. 2020 Nov 10. pii: 474126. doi: 10.1182/blood.2020007150.
    >> Share

  703. KHANAM T, Sandmann S, Seggewiss J, Ruether CM, et al
    Integrative genomic analysis of pediatric T- cell lymphoblastic lymphoma reveals candidates of clinical significance.
    Blood. 2020 Nov 5. pii: 474099. doi: 10.1182/blood.2020005381.
    >> Share

    July 2020
  704. BLOUIN JM, Ged C, Lalanne M, Lamrissi-Garcia I, et al
    Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria.
    Blood. 2020 Jul 17. pii: 461423. doi: 10.1182/blood.2020006037.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016